

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Effect of Diabetes Mellitus on Risk of Latent TB Infection after BCG Vaccination in A High TB Incidence Area: A Community-based Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029948
Article Type:	Research
Date Submitted by the Author:	28-Feb-2019
Complete List of Authors:	<p>Lin, Ching-Hsiung; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; Chung Shan Medical University, School of Medicine</p> <p>Kuo, Shu-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsieh, Ming-Chia; China Medical University, Graduate Institute of Integrative Medicine; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Ho, Shang-Yun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Su, Ih-Jen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Sheng-Hao; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; MingDao University, Department of Holistic Wellness</p> <p>Chi, Chia-Yu; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology; National Cheng Kung University Hospital, Department of Pediatrics</p> <p>Su, Shih-Li; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Liao, Chiung-Ying; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Chen, Yee-Chun; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsu, Shang-Ren; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Huang, Yuan-Chun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Tseng, Fan-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Wang, Shu Yi; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Dou, Horng Yunn; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Shi-Dou; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Lin, Jen-Shiou; Changhua Christian hospital, Department of Laboratory Medicine</p> <p>Tu, Shih-Te; Changhua Christian Hospital, Department of Internal</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	Medicine Yeh, Yen-Po; National Taiwan University, Innovation and Policy Center for Population Health and Sustainable Environment
Keywords:	Diabetes Mellitus, Tuberculosis < INFECTIOUS DISEASES, Latent Infection, Bacillus Calmette–Guérin vaccination



## Effect of Diabetes Mellitus on Risk of Latent TB Infection after BCG

### Vaccination in A High TB Incidence Area: A Community-based Study in Taiwan

**Running title:** Individuals with diabetes have a moderately increased risk of LTBI.

Ching-Hsiung Lin, MD, PHD<sup>1,2,3,4#</sup> Shu-Chen Kuo, MD<sup>5#</sup> Ming-Chia Hsieh, MD,  
PHD<sup>6,7</sup> Shang-Yun Ho, MD<sup>8</sup> Ih-Jen Su, MD, PHD<sup>5</sup> Sheng-Hao Lin, MD, PHD<sup>1,3</sup>  
Chia-Yu Chi, MD<sup>5,9</sup> Shih-Li Su, MD, PHD<sup>7</sup> Chiung-Ying Liao, MD<sup>8</sup> Yee-Chun Chen,  
MD, PHD<sup>5</sup> Shang-Ren Hsu, MD<sup>7</sup> Yuan-Chun Huang, MD<sup>8</sup> Fan-Chen Tseng, PHD<sup>5</sup>  
Shu Yi Wang, MD<sup>7</sup> Horng Yunn Dou, PHD<sup>5</sup> Shi-Dou Lin, MD<sup>7</sup> Jen-Shiou Lin,  
MD, PHD<sup>10</sup> (Ching-Hsiung Lin from Changhua Research Alliance for Tuberculosis  
Elimination) on behalf of Changhua Research Alliance for Tuberculosis  
Elimination,<sup>11</sup> Shih-Te Tu, MD<sup>7\*</sup> Yen-Po Yeh, MD, PHD<sup>12,13\*</sup>

<sup>1</sup> Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua

<sup>2</sup> School of Medicine, Chung Shan Medical University, Taichung, Taiwan

<sup>3</sup> Department of Holistic Wellness, MingDao University, Changhua, Taiwan

<sup>4</sup> Institute of Genomics and Bioinformatics

1  
2  
3  
4 <sup>5</sup> National Institute of Infectious Diseases and Vaccinology, National Health Research

5  
6  
7 Institutes, Miaoli, Taiwan

8  
9  
10 <sup>6</sup> Graduate Institute of Integrative Medicine, China Medical University, Taichung,

11  
12  
13 Taiwan

14  
15  
16 <sup>7</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine,

17  
18  
19 Changhua Christian Hospital, Changhua, Taiwan

20  
21  
22 <sup>8</sup> Department of Medical Imaging, ChangHua Christian Hospital

23  
24  
25 <sup>9</sup> Department of Pediatrics, National Cheng Kung University Hospital, Tainan,

26  
27  
28 Taiwan

29  
30  
31 <sup>10</sup> Department of Laboratory Medicine, Changhua Christian hospital

32  
33  
34 <sup>11</sup> ChangHua Christian Hospital, Lukang Christian Hospita, Erlin Christian Hospital,

35  
36  
37 Yunlin Christian Hospital (Physician of Pulmonary Medicine and Department of

38  
39  
40 Metabolism); Physician of Changhua county township health clinics, Infectious

41  
42  
43 Diseases and Vaccine Institute, National Health Research Institutes.

44  
45  
46 <sup>12</sup> Changhua County Public Health Bureau

47  
48  
49 <sup>13</sup> Innovation and Policy Center for Population Health and Sustainable Environment,

50  
51  
52 College of Public Health, National Taiwan University, Taipei, Taiwan

53  
54  
55  
56  
57  
58 # Ching-Hsiung Lin and Shu-Chen Kuo are co-first author.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10 \*Corresponding authors:  
11

12  
13 Yen-Po Yeh  
14

15  
16 Changhua County Public Health Bureau  
17

18  
19 Tel: 886-4-7115141  
20

21  
22 Fax: 886-4-7115141  
23

24  
25 Email: yen-po-yeh@edusbm.com  
26  
27  
28  
29

30  
31 **Word Count: 2969**  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** To investigate the latent tuberculosis infections (LTBIs) in patients with diabetes, especially in high TB incidence areas with a high coverage of Bacillus Calmette–Guérin (BCG) vaccination.

**Design:** prospective

**Setting:** thirteen secondary health care facilities

**Participants:** A total of 2948 patients with diabetes who were older than 40 years were recruited, and 453 non-diabetic participants from the community were enrolled.

**Primary and secondary outcome measures:** The interferon-gamma release assay (IGRA) and the tuberculin skin test were used to detect LTBI. The IGRA result was used as a surrogate of LTBI in logistic regression analysis.

**Result:** Diabetes was significantly associated with LTBI and age correlated positively with LTBI. Many subjects with diabetes also had additional risk factors including current smokers, comorbid chronic kidney disease, and prior history of TB. The presence of a BCG scar was protective, and the adjusted odds ratio for LTBI was 0.69 for those with 1 scar and 0.49 for those with 2 or more scars. BCG protection was not modified by the DM status and persisted in middle-aged adulthood until it waned in old age. Duration of diabetes and poor glycaemic control were unrelated to the risk of LTBI.

1  
2  
3  
4 **Conclusion:** BCG prevented acquisition of TB infection in diabetes population. There  
5  
6  
7 was a moderately increased risk of LTBI in diabetes patients from this high TB  
8  
9  
10 incidence area. This finding suggests incorporating other risk factors and  
11  
12  
13 comorbidities, in addition to diabetes, to better identify high-risk groups and improve  
14  
15  
16 the efficacy of targeted screening for LTBI.  
17  
18  
19  
20  
21

22 **Keywords:** Diabetes Mellitus, Tuberculosis, Latent Infection, Bacillus  
23  
24  
25 Calmette–Guérin vaccination  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### Strengths and limitations of this study

1. A total of 2948 patients with diabetes who were older than 40 years were recruited.
2. The interferon-gamma release assay and the tuberculin skin test were used to detect latent tuberculosis infections.
3. Participants in this study might generally have better general health status because they were enrolled from the national diabetes disease management program, which may underestimate the risk of tuberculosis infection.

## Abbreviations

Bacillus Calmette–Guérin (BCG)

Changhua Christian Healthcare System (CCHS)

Changhua Community-based Integrated Screening (CHCIS)

Chronic kidney disease (CKD)

Diabetes mellitus (DM)

Glycated hemoglobin (HBA1c)

Interferon-gamma release assay (IGRA)

Latent TB infections (LTBIS)

Tuberculin skin test (TST)

Tuberculosis (TB)

For peer review only

## BACKGROUND

The co-occurrence of diabetes mellitus (DM) and tuberculosis (TB) cannot be overemphasized because of the high prevalence of each disease throughout the world. [1] Previous studies found that DM affects TB disease presentation, leads to poor treatment outcomes, and increases the risk for active TB.[1, 2] The recently published World Health Organization guideline recommends screening for active TB with DM,[3] but it remains elusive whether screening and treatment of latent TB infections (LTBIs) should be prioritized to target individuals with DM.[1, 4-6]

There is only limited information on the LTBI status of patients with DM. Most of antecedent relevant studies were in low TB incidence countries [7] or based on selected population by identifying DM in high-risk populations, such as TB contacts, immunocompromised patients with comorbid DM, or crisis-affected people. [6] The results of these studies are also inconsistent, mainly due to the different methods used to ascertain DM status (*e.g.* self-report, medical records, or laboratory testing) and differences in the control of potentially important confounders.[1, 5-7]

In high TB incidence areas, where most of TB infection occurred at young age before the onset of DM, the temporal relationship between DM and TB infection is different from that in low incidence areas (Figure 1).[6, 8] This temporal characteristic may lead to non-differential misclassification of DM-related TB

1  
2  
3  
4 infection in cross-sectional studies and therefore bias the association toward the null  
5  
6  
7 (Figure 1c).[6] It is also worth noting that Bacillus Calmette–Guérin (BCG) vaccine is  
8  
9  
10 widely used in high burden TB countries for childhood immunization against TB.  
11  
12  
13 Recent studies found BCG vaccine has a protective effect against TB infection in  
14  
15  
16 children [9] and can even last into adulthood.[10] Although several researches have  
17  
18  
19 been devoted to assessment of DM-LTBI association, rather less attention has been  
20  
21  
22 paid to confounding from the protection conferred by BCG vaccination in settings  
23  
24  
25 where coverage of BCG vaccination in study subjects was high. Furthermore, while  
26  
27  
28 DM occurs most often in middle-aged and older people, few attempts have been made  
29  
30  
31 in this population to examine whether BCG protection is modified by the status of  
32  
33  
34 DM and whether the protection wanes with age in older adults.

35  
36  
37 In this study, using data from community-based screening programs in an area  
38  
39  
40 with a high incidence of TB and a high coverage of BCG vaccination, we assessed the  
41  
42  
43 overall risk of LTBI in people with and without DM by carefully controlling for  
44  
45  
46 potential confounders, including BCG vaccination, risk of infection with TB,  
47  
48  
49 comorbidities, important lifestyle factors and DM severity. We also investigated the  
50  
51  
52 effect modification of DM and age on the protective effect of BCG vaccination.  
53  
54  
55  
56  
57

## 58 **METHODS**

59  
60

## **Patient and Public Involvement**

We conducted a community-based study that comprised DM and non-DM subjects by combining two community-based programs to investigate the effect of DM on risk of LTBI in Changhua, a county in Taiwan with a TB incidence of 58.7 per 100000 and a BCG vaccination coverage of around 99% in 2012.[11] The first program recruited the DM group from patients registered in the Changhua Diabetes Shared Care program [12] (CHDSC) to participate in the LTBI survey. The second recruited the community comparison (CC) group from participants of a community-based LTBI screening program. Due to the lack of a gold-standard test for LTBI, the tuberculin skin test (TST) was used in parallel with the interferon-gamma release assay (IGRA). All participants provided signed informed consent before enrollment. Both studies were approved by the Institutional Review Board of the Changhua Christian Hospital (numbers IRB:CCH-130102 and IRB:CCH-111012).

### **DM group**

Nearly 60% of DM patients in Changhua were enrolled in the national diabetes disease management program (DDMP) and registered in the CHDSC.[12] The DM status of enrollees was ascertained by certified physicians according to national guidelines. We prospectively invited all registered cases who were more than 40

1  
2  
3  
4 years-old, from April 1, 2013 to December 31, 2013, when they presented to diabetes  
5  
6  
7 outpatient clinics of the Changhua Christian Healthcare System (CCHS) or 13 nearby  
8  
9  
10 health centers in the surrounding townships. CCHS comprises one medical center and  
11  
12  
13 three branch hospitals, distributed evenly at different locations of the county, and  
14  
15  
16 covers urban and rural areas. Thus, the participants of this study were a representative  
17  
18  
19 sample of the total DM population.  
20  
21

22 All study subjects were screened for pulmonary TB based on respiratory  
23  
24 symptoms and chest X-rays upon entry into the study. Suspected cases submitted  
25  
26 sputum specimens for acid-fast bacilli smears and culture. The diagnosis of TB was  
27  
28 confirmed by chest specialists. Subjects were excluded if they had active pulmonary  
29  
30 TB, a life expectancy of less than 2 years, metastatic cancer, or organ failure (*e.g.*  
31  
32 TB, a life expectancy of less than 2 years, metastatic cancer, or organ failure (*e.g.*  
33  
34 severe liver disease [Child-Pugh Class B or C]) except chronic renal failure. The  
35  
36 included eligible DM cases then received a TST and IGRA for detection of LTBI.  
37  
38  
39  
40  
41  
42  
43  
44  
45

#### 46 **Community comparison group**

47  
48

49 The Changhua Community-based Integrated Screening (CHCIS) program, which  
50  
51 began in 2005, screens for neoplastic and non-neoplastic diseases (including DM and  
52  
53 pulmonary TB).[13] The method used to screen for pulmonary TB was the same as  
54  
55 that used in the DM group. We invited all consecutive attendees of the CHCIS  
56  
57  
58  
59  
60

1  
2  
3  
4 program within the major catchment area of the CCHS to participate in LTBI  
5  
6  
7 screening in May 1, 2011. Participants with known DM or newly screened DM (*i.e.*  
8  
9  
10 fasting plasma glucose [FPG]  $\geq$  126 mg/dL) were excluded.  
11  
12  
13  
14  
15

### 16 **Tests for LTBI**

17  
18  
19 Venous blood was collected for the QuantiFERON-TB Gold In-Tube test  
20  
21  
22 (QFT-GIT; Cellestis, Carnegie, Australia), which was performed in 2 stages,  
23  
24  
25 according the manufacturer's instructions. The cutoff for a positive result was 0.35  
26  
27  
28 IU/mL. The reaction of a nil control and a mitogen control were within the range  
29  
30  
31 provided by the manufacturer. After collection of blood samples for QFT-GIT, trained  
32  
33  
34 nurses administered the TST using 2 TU of PPD RT23 (Statens Serum Institut,  
35  
36  
37 Copenhagen, Denmark) by the Mantoux method, and inspected the presence of BCG  
38  
39  
40 scars. Tuberculin indurations were measured 48-72 h after injection using the  
41  
42  
43 palpation method, and a diameter of 10 mm or more was defined as positive. All TST  
44  
45  
46 procedures followed the national guidelines issued by the CDC of Taiwan.[14]  
47  
48  
49  
50  
51

### 52 **Data collection**

53  
54  
55 We examined the DDMP database, and abstracted demographic data and  
56  
57  
58 information on DM care in the one year before each subject's entry. This included  
59  
60

1  
2  
3  
4 duration of DM, glycated hemoglobin (HbA1c), blood pressure, lipid profile, renal  
5  
6  
7 function, and other related cardiovascular disease risk factors. We also linked  
8  
9  
10 individual data with the TB registry at the local health authority to assess whether  
11  
12  
13 each study subject had a prior history of TB or contact with TB.  
14  
15  
16  
17  
18

### 19 **Statistical analysis**

20  
21  
22 Although both TST and IGRA indicate a cellular immune response to  
23  
24  
25 *Mycobacterium tuberculosis* (MTB) and are useful for the diagnosis of LTBI, the two  
26  
27  
28 tests identified different population with distinct immunologic processes.[15]  
29  
30  
31 Tuberculin reactivity represents the cumulative effect of previous TB infection  
32  
33  
34 (caused by recent and/or remote infection) because after infection with TB, positive  
35  
36  
37 results often remain lifelong until old age. On the contrary, IGRA has a  
38  
39  
40 dose–response relationship with recent TB exposure but it wanes rapidly.[15, 16]  
41  
42  
43 Thus, for adjusting for the bias of DM-related TB infection resulting from the  
44  
45  
46 occurrence of TB before DM (Figure 1c) as explained earlier, we used the result of  
47  
48  
49 the QFT-GIT as a surrogate of LTBI status in the logistic regression models designed  
50  
51  
52 to identify risk factors for LTBI. The TST results were then included in the models for  
53  
54  
55 controlling the confounding of remote TB infection. We also tested for effect  
56  
57  
58 modification of BCG protection by age and DM by including interactions terms (ie.  
59  
60



Age×BCG scar and DM×BCG scar) in the regression analysis. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

## RESULTS

### Characteristics of Participants

We ultimately enrolled 2948 patients in the DM group and 453 non-DM subjects in CC group, and included all of these individuals in the final analysis (Figure 2). The mean duration of DM in the DM group was 9.0 years (standard deviation [SD]=6.6) and nearly half of these patients achieved good glyceemic control (*i.e.* HbA1c < 7%) (Table 1). The DM group had a greater mean age, higher percentages of males and smokers, greater prevalences of obesity, chronic kidney disease (CKD), and prior history of TB. The DM group also had a greater prevalence of tuberculin reactivity ( $\geq 15\text{mm}$ ) and of QFT-GIT positivity, and a higher proportion of indeterminate results (Table 1).

**Table 1.** Characteristics of the DM group and the community comparison (CC) group.

	DM group (n=2948)	CC group (n=453)	p
<b>Age, years</b>			
Mean (SD)	61.5 (9.3)	51.3 (10.5)	<b>&lt;0.001</b>
<50	304 (10.3%)	209 (46.1%)	
50-59	918 (31.1%)	137 (30.2%)	<b>&lt;0.001</b>
60-69	1123 (38.1%)	91 (20.1%)	
≥70	603 (20.5%)	16 (3.5%)	
<b>Sex</b>			
Male	1468 (49.8%)	109 (24.1%)	<b>&lt;0.001</b>
Female	1480 (50.2%)	344 (75.9%)	
<b>Prior history of TB</b>			
Yes	61 (2.1%)	4 (0.9%)	0.0852
No	2887 (97.9%)	449 (99.1%)	
<b>History of contact with TB</b>			
Yes	115 (3.9%)	65 (14.3%)	<b>&lt;0.001</b>
No	2283 (77.4%)	388 (85.7%)	
Unknown	550 (18.7%)	0 (0.0%)	
<b>BCG scar</b>			
Yes	2436 (82.6%)	440 (97.1%)	
1 scar	1481 (50.2%)		
2 scar	934 (31.7%)		<b>&lt;0.001</b>
≥2 scars	21 (0.7%)		
No	502 (17.0%)	13 (2.9%)	
Unknown	10 (0.3%)		
<b>BMI, kg/m<sup>2</sup></b>			
Underweight (<18.5)	50 (1.7%)	7 (1.5%)	
Normal (18.5-24.9)	1175 (39.9%)	274 (60.5%)	<b>&lt;0.001</b>
Overweight (25-29.9)	1265 (42.9%)	149 (32.9%)	
Obese (≥30)	458 (15.5%)	23 (5.1%)	
<b>Smoking status</b>			
Current	433 (14.7%)	31 (6.8%)	<b>&lt;0.001</b>
Quit	434 (14.7%)	34 (7.5%)	
Never	2081 (70.6%)	388 (85.7%)	
<b>Triglycerides, mg/dL</b>			
<150 mg/dl	1962 (66.6%)	371 (81.9%)	<b>&lt;0.001</b>
≥150	986 (33.4%)	82 (18.1%)	

HDL-C*			
Low	1336 (45.3%)	299 (66.0%)	<b>&lt;0.001</b>
Ideal	1612 (54.7%)	154 (34.0%)	
CKD**			
Yes	948 (32.2%)	57 (12.6%)	<b>&lt;0.001</b>
No	1941 (65.8%)	375 (82.8%)	
Unknown	59 (2.0%)	21 (4.6%)	
Duration of diabetes, years			
mean (SD)	9.0 (6.6)		
≤5	1077 (36.5%)		
>5	1871 (63.5%)		
HbA1c			
Mean (SD)	7.4 (1.5)		
<7%	1400 (47.5%)		
≥7%	1548 (52.5%)		
Unknown	6 (0.2%)		
TST positive			
≥ 5 mm	2280 (77.3%)	350 (77.3%)	0.9895
<5 mm	668 (22.7%)	103 (22.7%)	
≥ 10 mm	1665 (56.5%)	251 (55.4%)	0.6974
<10 mm	1283 (43.5%)	202 (44.6%)	
≥ 15 mm	890 (30.2%)	112 (24.7%)	<b>0.0211</b>
<15mm	2058 (69.8%)	341 (75.3%)	
QFT-GIT			
Positive	623 (21.1%)	44 (9.7%)	<b>&lt;0.001</b>
Negative	2144 (72.7%)	406 (89.6%)	
Indeterminate	181 (6.1%)	3 (0.7%)	

Abbreviations: SD, standard deviation; HbA1c, glycated hemoglobin; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube.

\*Low HDL-C: <40 mg/dL (males) and <50 mg/dL (females).

\*\*CKD (chronic kidney disease) was assessed by the Modification of Diet in Renal Disease (MDRD) study equation, using the estimated glomerular filtration rate (eGFR).

### **TST and QFT-GIT results**

The presence of BCG scars had no effect on the tuberculin reactivity of the DM group (Figure 3a). TST positivity decreased with age, and was higher in the DM group than the CC group, except among the elderly. Figure 3b shows that QFT-GIT positivity of DM group was highest among those with no BCG scars, and that positivity declined dramatically in those more than 60 years-old. In contrast, the rate of QFT-GIT positivity in those with BCG scars gradually increased with age. For each age group, there was an inverse correlation between number of BCG scars and QFT-GIT positivity. Individuals in the CC group with BCG scars had the lowest QFT-GIT positivity, but elderly individuals from the CC group (age 70+) had the highest QFT-GIT positivity. Generally, the concordance between the TST and QFT-GIT was low (Supplementary Table 1).

### **Effect of DM and other factors on risk of LTBI**

Multivariate regression analysis indicates DM significantly increased the risk of LTBI after controlling for major confounders (aOR=1.67; 95%CI, 1.18-2.38). This risk was similar after adjustment for tuberculin reactivity (aOR=1.59; 95% CI, 1.11-2.28). In addition, the presence of LTBI increased with age. For age older than 70 years, TST adjustment had a marked effect and changed its aOR from 4.27 (95%

1  
2  
3  
4 CI, 2.83-6.44) to 2.98 (95% CI, 2.00-4.44). Other variables, such as current smoking,  
5  
6  
7 CKD, and prior history of TB, were also significant risk factors for LTBI, and their  
8  
9  
10 effects were similar with or without adjustment for tuberculin reactivity. Notably, the  
11  
12  
13 presence of a BCG scar had a significantly protective effect on LTBI (aOR=0.66  
14  
15  
16 [95%CI, 0.51-0.85]) (Table 2, Model 2); those with 1 scar had an aOR of 0.69 (95%  
17  
18  
19 CI, 0.52-0.90) and those with 2 or more scars had an aOR of 0.49 (95% CI, 0.36-0.67)  
20  
21  
22 (Table 2, Model 1).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2.** Logistic regression analysis of factors associated with LTBI in the DM group (model 1) and in the DM and CC groups combined (model 2), without and with adjustment for TST results.

Variable	Model 1. DM group (n = 2767)				Model 2. DM and CC groups (n = 3217)		
	Crude OR (95% CI)	aOR (95% CI)	aOR (95% CI) (TST adjustment)		Crude OR (95% CI)	aOR (95% CI)	aOR (95% CI) (TST adjustment)
				Age×BCG <sup>§</sup>			
TST 10+	3.85 (3.11-4.76)		4.77 (3.80-5.99)	4.75 (3.79-5.97)	3.66 (2.99-4.49)		4.56 (3.67-5.66)
DM					2.68 (1.94-3.71)	1.67 (1.18-2.38)	1.59 (1.11-2.28)
Age, years							
<50	Reference	Reference	Reference	Reference	Reference	Reference	Reference
50-59	1.63 (1.11-2.41)	1.85 (1.23-2.79)	2.20 (1.45-3.32)	1.33 (0.27-6.48)	1.98 (1.42-2.76)	1.86 (1.30-2.65)	2.12 (1.48-3.05)
60-69	2.12 (1.45-3.09)	2.28 (1.52-3.41)	2.96 (1.97-4.47)	0.73 (0.16-3.39)	2.52 (1.83-3.49)	2.25 (1.58-3.20)	2.77 (1.93-3.97)
≥70	3.19 (2.15-4.71)	2.84 (1.82-4.45)	4.35 (2.74-6.89)	1.10 (0.24-4.95)	4.07 (2.89-5.71)	2.98 (2.00-4.44)	4.27 (2.83-6.44)
Age×BCG <sup>§</sup>							
<50				0.16 (0.04-0.75)			
50-59				0.34 (0.08-1.52)			
60-69				0.54 (0.12-2.40)			
≥70				5.23 (1.08-25.40)			
Male	1.28 (1.07-1.54)	1.19 (0.94-1.50)	1.09 (0.85-1.38)	1.11 (0.87-1.41)	1.41 (1.19-1.68)	1.22 (0.98-1.52)	1.12 (0.89-1.41)

Smoking Never Current Quit	Reference 1.53 (1.20-1.93) 0.93 (0.71-1.21)	Reference 1.61 (1.2-2.15) 0.88 (0.64-1.2)	Reference 1.36 (1.00-1.83) 0.82 (0.59-1.13)	Reference 1.38 (1.02-1.86) 0.83 (0.60-1.15)	Reference 1.54 (1.22-1.95) 1.00 (0.77-1.29)	Reference 1.49 (1.13-1.97) 0.87 (0.64-1.17)	Reference 1.28 (0.95-1.71) 0.82 (0.60-1.11)
CKD	1.46 (1.21-1.76)	1.20 (0.98-1.47)	1.30 (1.05-1.60)	1.29 (1.04-1.59)	1.56 (1.31-1.87)	1.17 (0.96-1.42)	1.26 (1.03-1.55)
DM 5+ yrs	0.95 (0.79-1.15)	0.84 (0.69-1.02)	0.79 (0.64-0.97)	0.78 (0.63-0.96)			
A1C 7+%	0.91 (0.76-1.08)	0.91 (0.75-1.10)	0.91 (0.75-1.11)	0.92 (0.76-1.12)			
BCG scar No Yes 1 scar 2+ scars	Reference 0.63 (0.50-0.79) 0.43 (0.33-0.56)	Reference 0.76 (0.59-0.99) 0.55 (0.41-0.74)	Reference 0.69 (0.52-0.90) 0.49 (0.36-0.67)		Reference 0.51 (0.41-0.63)	Reference 0.73 (0.57-0.93)	Reference 0.66 (0.51-0.85)
PHx TB	2.99 (1.78-5.03)	2.35 (1.36-4.05)	2.21 (1.25-3.91)	2.16 (1.22-3.83)	2.95 (1.78-4.89)	2.17 (1.28-3.68)	2.08 (1.19-3.63)
TB contact	0.82 (0.50-1.32)	0.83 (0.50-1.36)	0.75 (0.45-1.25)	0.73 (0.43-1.22)	0.75 (0.50-1.13)	0.92 (0.60-1.40)	0.86 (0.55-1.33)

Abbreviations: DM, the diabetes mellitus; CC, community comparison; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST 10+, results of tuberculin skin test  $\geq 10$ mm; BMI, body mass index; CKD, chronic kidney disease; DM 5+ yrs, duration of diabetes mellitus  $\geq 5$  years; A1C, glycated hemoglobin. PHx TB, prior history of TB. <sup>§</sup> Measure of effect modification of the association between LTBI and BCG scar by age on multiplicative scale.

1  
2  
3  
4 The interaction term DM×BCG scar added to the regression model did not show a  
5  
6  
7 significant effect. For assessing effect modification of the association between LTBI and  
8  
9 BCG vaccination by age, the people aged younger than 50 years without BCG scar were  
10  
11 taken as the reference group. The aORs of the interaction terms (age×BCG scar) were  
12  
13  
14 0.2 (95%CI, 0.0-0.7) for ages < 50 years, 0.3 (95%CI, 0.1-1.5) for ages 50-60 years, 0.5  
15  
16 (95%CI, 0.1-2.4) for ages 60-70 years, and 5.2 (95%CI, 1.1-25.4) for ages 70+ years  
17  
18 respectively. (Table 2, Model 1)  
19  
20

21 Comorbidities, such as hyperlipidemia, hypertension, and abnormal body mass  
22  
23 index (BMI), had no significant associations with LTBI. We further investigated the  
24  
25 effect of long duration DM and poor glyceemic control by dividing the DM group into  
26  
27 four sub-groups according to duration of DM and HbA1c level, and then compared the  
28  
29 risk of LTBI of these different sub-groups, using the CC group as a reference. All of the  
30  
31 DM sub-groups had similar risks for LTBI. This indicates that long duration of DM and  
32  
33 poor glyceemic control had no effect on the risk of LTBI (Supplementary Table 2).  
34  
35  
36 However, among the DM group, those people with DM history for 5+ years had an aOR  
37  
38 of 0.78 (95%CI, 0.63-0.96) (Table 2, Model 1).  
39  
40  
41  
42  
43  
44

## 45 DISCUSSION

46  
47 Very few studies have examined the effect of DM on the risk of LTBI in high TB  
48  
49 incidence areas and simultaneously taken into account the protection of BCG against TB  
50  
51 infection. To our best knowledge, this is the first study to describe the association  
52  
53 between LTBI and BCG vaccination in diabetes population. In this community-based  
54  
55 study, we found BCG had a protective effect on TB infection in adults with an aOR of  
56  
57 0.66 (95%CI, 0.51-0.85), which did not vary by the status of DM. BCG protection  
58  
59  
60



1  
2  
3 correlated positively with the number of BCG scars. This effect also persisted in  
4  
5 middle-aged adulthood until it waned in old age. Meanwhile, by use of stringent  
6  
7 diagnostic criteria and adjusting for major confounding variables in an effort to  
8  
9 overcome the limitations of many previous studies, our multivariate analysis indicated  
10  
11 that DM had a positive association with risk of LTBI (aOR, 1.59 [95%CI, 1.11-2.28]). A  
12  
13 recently published population-based study in US, a country where BCG is not generally  
14  
15 recommended for use, using similar diagnostic criteria as this study, showed DM was  
16  
17 associated with LTBI with an aOR 1.5 (95% CI, 1.0–2.2),[7] very similar to our finding.  
18  
19  
20  
21

22 Until recently, there has been a scarcity of evidence on whether BCG can prevent  
23  
24 acquisition of TB infection because conventional measurement of LTBI utilizing TST  
25  
26 cannot distinguish if a positive response is due to MTB infection, or BCG vaccination,  
27  
28 or non-tuberculous mycobacterial (NTM) infection.[9, 17] Unlike TST, the recently  
29  
30 developed IGRAs use MTB specific antigens that do not cross react with BCG. Studies  
31  
32 have been conducted to investigate BCG protection on LTBI measured as positive  
33  
34 responses on IGRA. A recent meta-analysis of 14 studies and 3855 child or adolescent  
35  
36 participants (< 16 years) suggested that BCG is associated with protection from TB  
37  
38 infection (overall risk ratio, 0.81; 95% CI, 0.71 to 0.92).[9] Three additional studies in  
39  
40 high burden TB countries, not included in the meta-analysis, revealed that the protection  
41  
42 existed in young adults decades after BCG vaccination with aORs ranging from 0.6  
43  
44 (95%CI, 0.2–1.8) to 0.52 (95% CI, 0.32-0.85),[10, 18, 19] close to our estimate.  
45  
46  
47  
48

49 What is the duration of BCG protection against TB infection is a question not yet  
50  
51 determined. A long-term follow-up of trial participants of a BCG vaccine in US  
52  
53 Native-American populations reported good protective efficacy against TB disease that  
54  
55 extended up to 60 years after vaccination.[21] By contrast, new research using a  
56  
57 case–control study design in the UK found BCG protection lasted for 20 years.[22]  
58  
59  
60

1  
2  
3  
4 Nonetheless, since in our regression model, the aORs of interaction terms DM×BCG  
5  
6 raised dramatically to 5.2 (95%CI, 1.1-25.4) in the age group of 70+ years (i.e. a cohort  
7  
8 of school-aged BCG vaccination as described above), it is reasonable to assume that  
9  
10 BCG protection against TB infection may last 60 years and then waned, an estimate in  
11  
12 accordance with the US study.  
13  
14

15  
16 Since DM is a progressive disease, longer diabetes duration was found to be a  
17  
18 major predictor of DM-related complications and death, independent of glyceemic  
19  
20 control.[23] An earlier study also revealed the risk of developing TB disease increased  
21  
22 among those with increasing diabetes severity.[2] Thus, in this study, we investigated  
23  
24 the combined effect of longer duration of DM and poor glyceemic control  
25  
26 (Supplementary Table 2). We found they did not affect the risk of LTBI. Similarly,  
27  
28 association between glyceemic control and risk of TB was not observed in other studies  
29  
30 targeting DM cases under routine medical care for years.[26, 27]  
31  
32

33  
34 Many of the subjects with DM in the present study also smoked (14.7%), had  
35  
36 abnormal BMIs (overweight and obese, 58.4%; underweight, 1.7%), CKD (32.2%),  
37  
38 prior history of TB (2.1%), and advanced age (58.6% older than 60 years), and these  
39  
40 may also be risk factors for TB.[30-32] We found that each factor alone had only a mild  
41  
42 to moderate association with LTBI (Table 2) after adjustment of BCG protection.  
43  
44 However, when an individual has all of these other factors as well as DM, there may be  
45  
46 a particularly high-risk of LTBI, especially in those who are elderly. For example, male  
47  
48 DM patients older than 60 years who smoke have an aOR of LTBI up to 6.7 (derived by  
49  
50 summation of the estimated regression coefficients). Conventional targeted screening for  
51  
52 LTBI mostly focuses on host variables and the environment, such as infectiousness of  
53  
54 index cases and contact patterns, but seldom consider the effects of multiple factors  
55  
56 simultaneously.[33, 34] Our results underscore the necessity of incorporating DM and  
57  
58  
59  
60

1  
2  
3 related risk factors to develop a composite scoring system that improves the efficacy of  
4  
5 LTBI screening programs.  
6

7  
8 There are some limitations in our study. First, although the *in vivo* TST and *ex vivo*  
9  
10 IGRAs are the only two methods available for diagnosing LTBI, there is concern that  
11  
12 immune dysfunction in DM may compromise the performance of these tests.[5] Second,  
13  
14 all DM patients were enrolled from the DDMP, an intervention designed to facilitate  
15  
16 lifestyle modification in patients with DM.[12] Thus, these study subjects may have  
17  
18 better general health status, and hence lower risk of TB infection, than DM patients from  
19  
20 the general population.[27]  
21  
22

23  
24 The comorbidity of TB and DM is due to the interaction between DM-impaired  
25  
26 immunity and the occurrence of active TB by endogenous reactivation (Figure 1c) or  
27  
28 exogenous new or reinfection (Figure 1a, 1b).[1, 5] This process is further complicated  
29  
30 by the protection conferred from BCG vaccination, social environment, the co-existence  
31  
32 of multiple non-communicable risk factors and other related comorbidities and  
33  
34 complications.[5, 32, 40] We tried to control for all possible confounders, but this  
35  
36 remains challenging due to the lack of a gold standard for diagnosis of LTBI and the  
37  
38 presence of only limited tools to identify DM patients who have the greatest risk of  
39  
40 progressing to active TB. Studies are therefore required to identify the predictive value  
41  
42 for progression to active TB based on IGRA and/or TST results in patients with DM.  
43  
44  
45 There is an ongoing longitudinal study of the present study cohort.  
46  
47  
48  
49  
50

## 51 **CONCLUSION**

52  
53 In conclusion, our study demonstrated BCG had an apparent protective effect on  
54  
55 TB infection in adults and there were a 1.59-fold increased risk of LTBI in patients with  
56  
57 DM from a geographic area that has a high incidence of TB and a high coverage of BCG  
58  
59  
60

1  
2  
3 vaccination. This finding suggests that practitioners should incorporate other coexisting  
4 risk factors and comorbidities, in addition to DM, to better identify high-risk groups and  
5  
6 enhance the efficacy of targeted screening for LTBI. Efficacy of new vaccines against  
7  
8 TB infection should be a major focus of TB vaccine development.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## DECLARATIONS

### Authors' contributions:

- 1 Guarantor of integrity of the entire study: Ching-Hsiung Lin, Shu-Chen Kuo,  
2 Yen-Po Yeh, Shih-Te Tu
- 3 study concepts: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su,  
4 Sheng-Hao Lin , Yen-Po Yeh, Shih-Te Tu
- 5 study design: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su,  
6 Sheng-Hao Lin , Yen-Po Yeh, Shih-Te Tu
- 7 definition of intellectual content: Ching-Hsiung Lin, Shu-Chen Kuo, Ih-Jen Su,  
8 Yee-Chun Chen, Yen-Po Yeh, Shih-Te Tu
- 9 literature research: Shu-Chen Kuo, Ming-Chia Hsieh, Chia-Yu Chi, Yee-Chun Chen,  
10 Horng Yunn Dou
- 11 clinical studies: Ming-Chia Hsieh, Ching-Hsiung Lin, Shang-Yun Ho, Sheng-Hao  
12 Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi  
13 Wang, Shi-Dou Lin, Yen-Po Yeh, Shih-Te Tu
- 14 experimental studies: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen  
15 Su, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Horng Yunn Dou  
16 Jen-Shiou Lin, Yen-Po Yeh, Shih-Te Tu
- 17 data acquisition: Ming-Chia Hsieh, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su,  
18 Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin
- 19 data analysis: Shu-Chen Kuo, Ming-Chia Hsieh, Shang-Yun Ho, Chia-Yu Chi,  
20 Chiung-Ying Liao, Yuan-Chun Huang, Fan-Chen Tseng, Yen-Po Yeh, Shih-Te Tu
- 21 statistical analysis: Ming-Chia Hsieh, Fan-Chen Tseng, Yen-Po Yeh,
- 22 manuscript preparation: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po  
23 Yeh, Shih-Te Tu

1  
2  
3 12 manuscript editing: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po  
4  
5 Yeh, Shih-Te Tu  
6

7  
8 13 manuscript review: Ching-Hsiung Lin, Ming-Chia Hsieh, Sheng-Hao Lin ,  
9  
10 Yee-Chun Chen, Yen-Po Yeh, Shih-Te Tu  
11

### 12 13 14 15 **Acknowledgement**

16  
17 The authors wish to acknowledge the assistance of Statistics experts: Dr. Chao-Chih Lai  
18  
19 from Emergency Department, Taipei City Hospital, Ren-Ai Branch, Taiwan and  
20  
21 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health,  
22  
23 National Taiwan University, Division Biostatistics, Taipei Taiwan; Professor Hsiu-Hsi  
24  
25 Chen from Graduate Institute of Epidemiology and Preventive Medicine, College of  
26  
27 Public Health, National Taiwan University, Division Biostatistics, Taipei Taiwan; Dr.  
28  
29 ChenYang Hsu from Graduate Institute of Epidemiology and Prevention Medicine,  
30  
31 College of Public Health, National Taiwan University. The authors also express special  
32  
33 thanks to the Physician at the Changhua Health Bureau and the Physician at Department  
34  
35 of Metabolism, ChangHua Christian Hospital for their assistance in the  
36  
37 community-based study. This work was supported by the "Innovation and Policy Center  
38  
39 for Population Health and Sustainable Environment (Population Health Research Center,  
40  
41 PHRC), College of Public Health, National Taiwan University" from The Featured  
42  
43 Areas Research Center Programme within the framework of the Higher Education  
44  
45 Sprout Project by the Ministry of Education (MOE) in Taiwan.  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Conflict of interest statements:**

55  
56 All authors declare that they have no conflict of interest.  
57  
58  
59  
60

**Role of funding source:**

This study is supported by the Funding sponsorship plan of National Health Research Institutes: “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan -A study on Evolution, Toxicity and Drug Resistance of Mycobacterium Tuberculosis (IV-102-SP-08)” and “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan - A Study on the Evolution of Tuberculosis Genes and Transcripts in Tuberculosis Recurrence(IV-103-SP-06, IV-104-SP-06)”; the Funding sponsorship plan of ChangHua Christian Hospital: “Risk assessment of TB reactivation and efficacy of preventive therapy in latent TB infection population in Changhua county (102-CCH-PRJ-03)”. Yen-Po Yeh is supported by the Ministry of Science and Technology grant (grant number MOST 107-3017-F-002-003) and The Featured Areas Research Center Programme within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). The founders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Ethics committee approval:**

All participants provided signed informed consent before enrollment. Both studies were approved by the Institutional Review Board of the Changhua Christian Hospital (numbers IRB:CCH-130102 and IRB:CCH-111012).

**Availability of data and material:** Not applicable.

**Consent for publication:** Not applicable.

**REFERENCE**

- 1 Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;**9**:737-46.
- 2 Baker MA, Harries AD, Jeon CY, *et al*. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011;**9**:81.
- 3 WHO Guidelines Approved by the Guidelines Review Committee. *Systematic Screening for Active Tuberculosis: Principles and Recommendations*. Geneva: World Health Organization  
Copyright (c) World Health Organization 2013. 2013.
- 4 WHO Guidelines Approved by the Guidelines Review Committee. *Collaborative Framework for Care and Control of Tuberculosis and Diabetes*. Geneva: World Health Organization  
Copyright (c) World Health Organization 2011. 2011.
- 5 Restrepo BI. Diabetes and Tuberculosis. *Microbiol Spectr* 2016;**4**.
- 6 Lee MR, Huang YP, Kuo YT, *et al*. Diabetes Mellitus and Latent Tuberculosis Infection: A Systemic Review and Metaanalysis. *Clin Infect Dis* 2017;**64**:719-27.
- 7 Martinez L, Zhu L, Castellanos ME, *et al*. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. *Clin Infect Dis* 2017;**65**:2060-8.
- 8 Yeh YP, Luh DL, Chang SH, *et al*. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. *Trans R Soc Trop Med Hyg* 2005;**99**:509-16.
- 9 Roy A, Eisenhut M, Harris RJ, *et al*. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. *BMJ* 2014;**349**:g4643.



- 1  
2  
3 10 Chan PC, Yang CH, Chang LY, *et al.* Lower prevalence of tuberculosis infection in  
4 BCG vaccinees: a cross-sectional study in adult prison inmates. *Thorax* 2013;**68**:263-8.  
5  
6  
7 11 CDC D, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. Centres for  
8 Disease Control, Department of Health, R.O.C. 2014.  
9  
10  
11 12 Yeh YP, Chang CJ, Hsieh ML, *et al.* Overcoming disparities in diabetes care: eight  
12 years' experience changing the diabetes care system in Changhua, Taiwan. *Diabetes Res*  
13 *Clin Pract* 2014;**106 Suppl 2**:S314-22.  
14  
15  
16 13 Chen TH, Chiu YH, Luh DL, *et al.* Community-based multiple screening model:  
17 design, implementation, and analysis of 42,387 participants. *Cancer* 2004;**100**:1734-43.  
18  
19  
20 14 CDC D, R.O.C. (Taiwan). TB Control Manual, 2nd edn Centres for Disease  
21 Control, Department of Health, R.O.C. 2009.  
22  
23  
24 15 Lai CC, Hsieh YC, Yeh YP, *et al.* A pulmonary tuberculosis outbreak in a  
25 long-term care facility. *Epidemiol Infect* 2016;**144**:1455-62.  
26  
27  
28 16 Kang YA, Lee HW, Yoon HI, *et al.* Discrepancy between the tuberculin skin test  
29 and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis  
30 infection in an intermediate tuberculosis-burden country. *JAMA* 2005;**293**:2756-61.  
31  
32  
33 17 Hawn TR, Day TA, Scriba TJ, *et al.* Tuberculosis vaccines and prevention of  
34 infection. *Microbiol Mol Biol Rev* 2014;**78**:650-71.  
35  
36  
37 18 Michelsen SW, Soborg B, Koch A, *et al.* The effectiveness of BCG vaccination in  
38 preventing Mycobacterium tuberculosis infection and disease in Greenland. *Thorax*  
39 2014;**69**:851-6.  
40  
41  
42 19 Hill PC, Brookes RH, Fox A, *et al.* Longitudinal assessment of an ELISPOT test  
43 for Mycobacterium tuberculosis infection. *PLoS Med* 2007;**4**:e192.  
44  
45  
46 20 Mangtani P, Abubakar I, Ariti C, *et al.* Protection by BCG vaccine against  
47 tuberculosis: a systematic review of randomized controlled trials. *Clin Infect Dis*  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 2014;**58**:470-80.  
4

5 21 Aronson NE, Santosham M, Comstock GW, *et al*. Long-term efficacy of BCG  
6 vaccine in American Indians and Alaska Natives: A 60-year follow-up study. *JAMA*  
7 2004;**291**:2086-91.  
8  
9

10 22 Mangtani P, Nguipdop-Djomo P, Keogh RH, *et al*. The duration of protection of  
11 school-aged BCG vaccination in England: a population-based case-control study. *Int J*  
12 *Epidemiol* 2018;**47**:193-201.  
13  
14

15 23 Herrington WG, Alegre-Diaz J, Wade R, *et al*. Effect of diabetes duration and  
16 glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based  
17 prospective cohort study. *Lancet Diabetes Endocrinol* 2018;**6**:455-63.  
18  
19

20 24 Leung CC, Lam TH, Chan WM, *et al*. Diabetic control and risk of tuberculosis: a  
21 cohort study. *Am J Epidemiol* 2008;**167**:1486-94.  
22  
23

24 25 Lee PH, Fu H, Lai TC, *et al*. Glycemic Control and the Risk of Tuberculosis: A  
25 Cohort Study. *PLoS Med* 2016;**13**:e1002072.  
26  
27

28 26 Leegaard A, Riis A, Kornum JB, *et al*. Diabetes, glycemic control, and risk of  
29 tuberculosis: a population-based case-control study. *Diabetes Care* 2011;**34**:2530-5.  
30  
31

32 27 Pealing L, Wing K, Mathur R, *et al*. Risk of tuberculosis in patients with diabetes:  
33 population based cohort study using the UK Clinical Practice Research Datalink. *BMC*  
34 *Med* 2015;**13**:135.  
35  
36

37 28 Yokobayashi K, Kawachi I, Kondo K, *et al*. Association between Social  
38 Relationship and Glycemic Control among Older Japanese: JAGES Cross-Sectional  
39 Study. *PLoS One* 2017;**12**:e0169904.  
40  
41

42 29 Sparring V, Nystrom L, Wahlstrom R, *et al*. Diabetes duration and health-related  
43 quality of life in individuals with onset of diabetes in the age group 15-34 years - a  
44 Swedish population-based study using EQ-5D. *BMC Public Health* 2013;**13**:377.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 30 Romanowski K, Clark EG, Levin A, *et al.* Tuberculosis and chronic kidney disease:  
4 an emerging global syndemic. *Kidney Int* 2016;**90**:34-40.  
5  
6  
7  
8 31 Horsburgh CR, Jr., O'Donnell M, Chamblee S, *et al.* Revisiting rates of reactivation  
9 tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 2010;**182**:420-5.  
10  
11  
12 32 Dye C, Bourdin Trunz B, Lonnroth K, *et al.* Nutrition, diabetes and tuberculosis in  
13 the epidemiological transition. *PLoS One* 2011;**6**:e21161.  
14  
15  
16  
17 33 Fox GJ, Barry SE, Britton WJ, *et al.* Contact investigation for tuberculosis: a  
18 systematic review and meta-analysis. *Eur Respir J* 2013;**41**:140-56.  
19  
20  
21  
22 34 Aissa K, Madhi F, Ronsin N, *et al.* Evaluation of a model for efficient screening of  
23 tuberculosis contact subjects. *Am J Respir Crit Care Med* 2008;**177**:1041-7.  
24  
25  
26  
27 35 Kwon YS, Kim YH, Jeon K, *et al.* Factors that Predict Negative Results of  
28 QuantiFERON-TB Gold In-Tube Test in Patients with Culture-Confirmed Tuberculosis:  
29 A Multicenter Retrospective Cohort Study. *PLoS One* 2015;**10**:e0129792.  
30  
31  
32  
33 36 Hsu CC, Lee CH, Wahlqvist ML, *et al.* Poverty increases type 2 diabetes incidence  
34 and inequality of care despite universal health coverage. *Diabetes Care*  
35 2012;**35**:2286-92.  
36  
37  
38  
39 37 Ribeiro FK, Pan W, Bertolde A, *et al.* Genotypic and Spatial Analysis of  
40 Mycobacterium tuberculosis Transmission in a High-Incidence Urban Setting. *Clin*  
41 *Infect Dis* 2015;**61**:758-66.  
42  
43  
44  
45  
46  
47 38 Chen PC, Tsai CY, Woung LC, *et al.* Socioeconomic disparities in preventable  
48 hospitalization among adults with diabetes in Taiwan: a multilevel modelling approach.  
49 *Int J Equity Health* 2015;**14**:31.  
50  
51  
52  
53  
54 39 Chang RE, Lin SP, Aron DC. A pay-for-performance program in Taiwan improved  
55 care for some diabetes patients, but doctors may have excluded sicker ones. *Health Aff*  
56 *(Millwood)* 2012;**31**:93-102.  
57  
58  
59  
60

1  
2  
3 40 Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. *Eur J Immunol*  
4  
5 2014;**44**:617-26.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## FIGURE LEGENDS

**Figure 1** Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM before the primary TB infection. (b) Onset of DM with a pre-existing latent TB infection (LTBI), but before re-infection. (c) Onset of DM with pre-existing LTBI.


**Figure 2** Patient selection and enrolment in the DM group (left) and the CC group (right).

Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

**Figure 3** Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DM group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.


Figure 1




99x65mm (300 x 300 DPI)

Figure 2

(a) DM group




(b) Community comparison group




99x65mm (300 x 300 DPI)

Figure 3

(a)



(b)



99x127mm (300 x 300 DPI)



**Supplementary Table 1.** Agreement between TST and QFT-GIT

Results	Overall n = 3217			DM group n = 2767			CC group n = 450		
	TST cut point			TST cut point			TST cut point		
	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm
TST+/QFT-GIT+	613	528	363	37	32	23	576	496	340
TST-/QFT-GIT-	664	1252	1950	95	188	318	569	1064	1632
TST+/QFT-GIT-	1886	1298	600	311	218	88	1575	1080	512
TST-/QFT-GIT+	54	139	304	7	12	21	47	127	283
Agreement%	39.7%	55.3%	71.9%	29.3%	48.9%	75.8%	41.4%	56.4%	71.3%
Kappa (95% CI)	0.09 (0.74-0.10)	0.17 (0.15-0.20)	0.27 (0.23-0.30)	0.10 (0.08-0.12)	0.19 (0.16-0.22)	0.27 (0.23-0.31)	0.02 (-0.01-0.05)	0.06 (0.01-0.11)	0.18 (0.09-0.28)

Abbreviations: TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube; CI, confidence interval.

Test results with an indeterminate QFT-GIT response are not included in the table.

**Supplementary Table 2.** Combined effects of glyceimic control (HbA1c) and duration of DM on risk of latent tuberculosis infection without and with adjustment for TST results.

Variables	Crude OR (95% CI)	aOR* (95% CI)	aOR* (95% CI) (TST adjustment)
Community comparison group			
A1C $\geq$ 7%, duration >5 years	Reference 2.49 (1.77-3.52)	Reference 1.42 (0.97-2.07)	Reference 1.33 (0.90-1.96)
A1C $\geq$ 7%, duration $\leq$ 5 years	2.71 (1.84-3.98)	1.87 (1.24-2.82)	1.80 (1.18-2.74)
A1C <7%, duration >5 years	2.84 (1.99-4.04)	1.67 (1.13-2.46)	1.54 (1.03-2.28)
A1C <7%, duration $\leq$ 5 years	2.81 (1.95-4.04)	1.84 (1.24-2.72)	1.82 (1.22-2.72)

Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST, tuberculin skin test; A1C, glycated hemoglobin.

\*The multivariable model adjusted for the comorbidities indicated in Table 3, Model 2.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9
Objectives	3	State specific objectives, including any pre-specified hypotheses	9
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10-12
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-12
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	10-11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	14
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	14-16
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	17-21
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	17-21
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	17-21
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	17-21
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17-21
		(b) Report category boundaries when continuous variables were categorized	17-21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	21-25
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	24
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	24-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	24-25
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of Diabetes Mellitus on Risk of Latent TB Infection after BCG Vaccination in A High TB Incidence Area: A Community-based Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029948.R1
Article Type:	Original research
Date Submitted by the Author:	11-Jun-2019
Complete List of Authors:	<p>Lin, Ching-Hsiung; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; Chung Shan Medical University, School of Medicine</p> <p>Kuo, Shu-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsieh, Ming-Chia; China Medical University, Graduate Institute of Integrative Medicine; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Ho, Shang-Yun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Su, Ih-Jen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Sheng-Hao; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; MingDao University, Department of Holistic Wellness</p> <p>Chi, Chia-Yu; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology; National Cheng Kung University Hospital, Department of Pediatrics</p> <p>Su, Shih-Li; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Liao, Chiung-Ying; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Chen, Yee-Chun; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsu, Shang-Ren; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Huang, Yuan-Chun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Tseng, Fan-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Wang, Shu Yi; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Dou, Horng Yunn; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Shi-Dou; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Lin, Jen-Shiou; Changhua Christian hospital, Department of Laboratory Medicine</p> <p>Tu, Shih-Te; Changhua Christian Hospital, Department of Internal</p>

	Medicine Yeh, Yen-Po; National Taiwan University, Innovation and Policy Center for Population Health and Sustainable Environment; Changhua Public Health Bureau
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Immunology (including allergy), Respiratory medicine
Keywords:	Diabetes Mellitus, Tuberculosis < INFECTIOUS DISEASES, Latent Infection, Bacillus Calmette–Guérin vaccination, Interferon gamma release essay, Tuberculin skin test

SCHOLARONE™  
Manuscripts

1  
2  
3 **Effect of Diabetes Mellitus on Risk of Latent TB Infection after BCG Vaccination**  
4  
5 **in A High TB Incidence Area: A Community-based Study in Taiwan**  
6  
7  
8  
9

10 **Running title:** Individuals with diabetes have a moderately increased risk of LTBI.  
11  
12  
13

14 Ching-Hsiung Lin, MD, PHD<sup>1,2,3,4#</sup> Shu-Chen Kuo, MD<sup>5#</sup> Ming-Chia Hsieh, MD,  
15 PHD<sup>6,7</sup> Shang-Yun Ho, MD<sup>8</sup> Ih-Jen Su, MD, PHD<sup>5</sup> Sheng-Hao Lin, MD, PHD<sup>1,3</sup> Chia-  
16 Yu Chi, MD<sup>5,9</sup> Shih-Li Su, MD, PHD<sup>7</sup> Chiung-Ying Liao, MD<sup>8</sup> Yee-Chun Chen,  
17 MD, PHD<sup>5</sup> Shang-Ren Hsu, MD<sup>7</sup> Yuan-Chun Huang, MD<sup>8</sup> Fan-Chen Tseng, PHD<sup>5</sup> Shu  
18 Yi Wang, MD<sup>7</sup> Horng Yunn Dou, PHD<sup>5</sup> Shi-Dou Lin, MD<sup>7</sup> Jen-Shiou Lin, MD, PHD<sup>10</sup>  
19 (Ching-Hsiung Lin from Changhua Research Alliance for Tuberculosis Elimination) on  
20 behalf of Changhua Research Alliance for Tuberculosis Elimination,<sup>11</sup> Shih-Te Tu,  
21 MD<sup>7\*</sup> Yen-Po Yeh, MD, PHD<sup>12,13\*</sup>  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 <sup>1</sup> Department of Internal Medicine, Division of Chest Medicine, Changhua Christian  
36 Hospital, Changhua  
37

38 <sup>2</sup> School of Medicine, Chung Shan Medical University, Taichung, Taiwan  
39

40 <sup>3</sup> Department of Holistic Wellness, MingDao University, Changhua, Taiwan  
41

42 <sup>4</sup> Institute of Genomics and Bioinformatics  
43

44 <sup>5</sup> National Institute of Infectious Diseases and Vaccinology, National Health Research  
45 Institutes, Miaoli, Taiwan  
46  
47  
48

49 <sup>6</sup> Graduate Institute of Integrative Medicine, China Medical University, Taichung,  
50 Taiwan  
51  
52

53 <sup>7</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine,  
54 Changhua Christian Hospital, Changhua, Taiwan  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<sup>8</sup> Department of Medical Imaging, ChangHua Christian Hospital

<sup>9</sup> Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan

<sup>10</sup> Department of Laboratory Medicine, Changhua Christian hospital

<sup>11</sup> ChangHua Christian Hospital, Lukang Christian Hospita, Erlin Christian Hospital,

Yunlin Christian Hospital (Physician of Pulmonary Medicine and Department of

Metabolism); Physician of Changhua county township health clinics, Infectious Diseases

and Vaccine Institute, National Health Research Institutes.

<sup>12</sup> Changhua County Public Health Bureau

<sup>13</sup> Innovation and Policy Center for Population Health and Sustainable Environment,

College of Public Health, National Taiwan University, Taipei, Taiwan

# Ching-Hsiung Lin and Shu-Chen Kuo are co-first author.

\*Corresponding authors:

Yen-Po Yeh

Changhua County Public Health Bureau

Tel: 886-4-7115141

Fax: 886-4-7115141

Email: lgyeh@hotmail.com

**Word Count: 3421**



## ABSTRACT

**Objectives:** To investigate latent tuberculosis infections (LTBIs) in patients with diabetes, especially in high TB incidence areas with a high coverage of BCG vaccination.

**Design:** Community-based comparison study

**Setting:** Outpatient diabetes clinics at 4 hospitals and 13 health centers in urban and rural townships. A community-based screening program was used to recruit non-diabetic participants.

**Participants:** A total of 2948 patients with diabetes aged older than 40 years were recruited, and 453 non-diabetic participants from the community were enrolled.

**Primary and secondary outcome measures:** The interferon-gamma release assay (IGRA) and the tuberculin skin test were used to detect LTBI. The IGRA result was used as a surrogate of LTBI in logistic regression analysis.

**Result:** Diabetes was significantly associated with LTBI ([aOR] = 1.59; 95% CI, 1.11-2.28) and age correlated positively with LTBI. Many subjects with diabetes also had additional risk factors (current smokers [aOR]=1.28; 95% CI, 0.95-1.71], comorbid chronic kidney disease [aOR = 1.26; 95% CI, 1.03-1.55], and prior history of TB [aOR = 2.08; 95% CI, 1.19-3.63]). The presence of a BCG scar was protective, and the adjusted odds ratio for LTBI was 0.69 (95% CI, 0.52-0.90) for those with 1 scar and 0.49 (95% CI, 0.36-0.67) for those with 2 or more scars. BCG protection was not modified by the DM status and persisted in middle-aged adulthood until it waned in old age. Duration of diabetes and poor glycemic control were unrelated to the risk of LTBI.

**Conclusion:** BCG prevented acquisition of TB infection in diabetes population. There was a moderately increased risk of LTBI in diabetes patients from this high TB incidence area. This finding suggests incorporating BCG vaccination, comorbidities and

1  
2  
3 other risk factors, in addition to diabetes, to better identify high-risk groups and improve  
4  
5 the efficacy of targeted screening for LTBI.  
6  
7  
8  
9

10 **Keywords:** Diabetes Mellitus, Tuberculosis, Latent Infection, Bacillus Calmette–Guérin  
11  
12 vaccination, Interferon-gamma release assay, Tuberculin skin test  
13  
14  
15  
16

### 17 **Strengths and limitations of this study**

- 18  
19 1. A total of 2948 patients with diabetes (DM) aged older than 40 years were recruited.
- 20  
21 2. The interferon-gamma release assay and the tuberculin skin test (TST) were used to  
22  
23 detect latent tuberculosis infections (LTBIs). TST results were included in the regression  
24  
25 models for adjusting the effect of remote TB infection.  
26  
27
- 28 3. BCG vaccine has a protective effect against TB infection in DM population, whose  
29  
30 confounding was controlled for assessing overall risk of LTBI in people with and  
31  
32 without DM.  
33  
34
- 35 4. DM Participants in this study might generally have better general health status  
36  
37 because they were enrolled from the national diabetes disease management program,  
38  
39 which may underestimate the risk of LTBI.  
40  
41  
42  
43  
44

### 45 **Abbreviations**

46 Bacillus Calmette–Guérin (BCG)

47 Changhua Christian Healthcare System (CCHS)

48 Changhua Community-based Integrated Screening (CHCIS)

49 Chronic kidney disease (CKD)

50 Diabetes mellitus (DM)

51 Glycated hemoglobin (HbA1c)  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Interferon-gamma release assay (IGRA)  
4

5 Latent TB infection (LTBI)  
6

7 Tuberculin skin test (TST)  
8

9 Tuberculosis (TB)  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## BACKGROUND

The co-occurrence of diabetes mellitus (DM) and tuberculosis (TB) cannot be overemphasized because of the high prevalence of each disease throughout the world [1]. Previous studies found that DM affects TB disease presentation, leads to poor treatment outcomes, and increases the risk for active TB [1, 2]. The recently published World Health Organization guideline recommends screening for active TB with DM [3], but it remains elusive whether screening and treatment of latent TB infections (LTBIs) should be prioritized to target individuals with DM [1, 4-6].

There is only limited information on the LTBI status of patients with DM. Most of antecedent relevant studies were in low TB incidence countries [7] or based on selected population by identifying DM in high-risk populations, such as TB contacts, immunocompromised patients with comorbid DM, or crisis-affected people [6]. The results of these studies are also inconsistent, mainly due to the different methods used to ascertain DM status (*e.g.* self-report, medical records, or laboratory testing) and differences in the control of potentially important confounders [1, 5-7].

In high TB incidence areas, where most of TB infection occurred at young age before the onset of DM [8], the temporal relationship between DM and TB infection is different from that in low incidence areas (Figure 1a-1b v.s. 1c) [6]. This temporal characteristic may lead to non-differential misclassification of DM-related TB infection in cross-sectional studies and therefore bias the association toward the null (Figure 1a) [6]. It is also worth noting that *Bacillus Calmette–Guérin* (BCG) vaccine is widely used in high burden TB countries for childhood immunization against TB. Recent studies found BCG vaccine has a protective effect against TB infection in children [9] and can even last into adulthood [10]. Although several researches have been devoted to assessment of DM-LTBI association, rather less attention has been paid to confounding

1  
2  
3 from the protection conferred by BCG vaccination in settings where coverage of BCG  
4 vaccination in study subjects was high. Furthermore, while DM occurs most often in  
5 middle-aged and older people, few attempts have been made in this population to  
6 examine whether BCG protection is modified by the status of DM and whether the  
7 protection wanes with age in older adults.  
8  
9

10  
11  
12 In this study, using data from community-based programs in an area with a high  
13 incidence of TB and a high coverage of BCG vaccination, we assessed the overall risk of  
14 LTBI in people with and without DM by carefully controlling for potential confounders,  
15 specifically including BCG vaccination, risk of remote TB infection, comorbidities,  
16 important lifestyle factors and DM severity. We also investigated the effect modification  
17 of DM and age on the protective effect of BCG vaccination.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## 30 **METHODS**

31  
32 We conducted a community-based study that comprised DM and non-DM subjects  
33 by combining two community-based programs to investigate the effect of DM on risk of  
34 LTBI in Changhua, a county in Taiwan with a TB incidence of 58.7 per 100000 and a  
35 BCG vaccination coverage of around 99% in 2012 [11]. The first program recruited the  
36 DM group from patients registered in the Changhua Diabetes Shared Care program  
37 (CHDSC) [12] to participate in the LTBI survey. The second recruited the community  
38 comparison (CC) group from participants of a community-based LTBI screening  
39 program [13]. Due to the lack of a gold-standard test for LTBI, the tuberculin skin test  
40 (TST) was used in parallel with the interferon-gamma release assay (IGRA). All  
41 participants provided signed informed consent before enrollment. Both studies were  
42 approved by the Institutional Review Board of the Changhua Christian Hospital  
43 (numbers IRB:CCH-130102 and IRB:CCH-111012).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DM group

Nearly 60% of DM patients in Changhua were enrolled in the national diabetes disease management program (DDMP) and registered in the CHDSC [12]. These enrollees were suitable to be included as the study subjects, because their DM status had been ascertained by certified physicians who provided diabetes care according to national guidelines. We prospectively invited all those registered DM cases aged older than 40 years when they presented to outpatient diabetes clinics of the Changhua Christian Healthcare System (CCHS) or 13 nearby health centers in the surrounding townships from April 1, 2013 to December 31, 2013. CCHS comprises one medical center and three branch hospitals, distributed evenly at different locations of the county, and covers urban and rural areas. Thus, the participants of this study were a representative sample of the total DM population.

All study subjects were screened for pulmonary TB based on respiratory symptoms and chest X-rays upon entry into the study. Suspected cases submitted sputum specimens for acid-fast bacilli smears and culture. The diagnosis of TB was confirmed by chest specialists. Subjects were excluded if they had active pulmonary TB, a life expectancy of less than 2 years, metastatic cancer, or organ failure (*e.g.* severe liver disease [Child-Pugh Class B or C]) except chronic renal failure. The included eligible DM cases then received a TST and IGRA for detection of LTBI.

## Community comparison group

The Changhua Community-based Integrated Screening (CHCIS) program, which began in 2005, screens for neoplastic and non-neoplastic diseases (including DM and pulmonary TB) [13]. The method used to screen for pulmonary TB was the same as that

1  
2  
3 used in the DM group. We invited all consecutive attendees of the CHCIS program  
4  
5 within the major catchment area of the CCHS to participate in LTBI screening in May 1,  
6  
7 2011. Participants with known DM or newly screened DM (*i.e.* fasting plasma glucose  
8  
9 [FPG]  $\geq$  126 mg/dL) were excluded.  
10  
11  
12  
13  
14

### 15 **Tests for LTBI**

16  
17 Venous blood was collected for the QuantiFERON-TB Gold In-Tube test (QFT-  
18  
19 GIT; Cellestis, Carnegie, Australia), which was performed in 2 stages, according the  
20  
21 manufacturer's instructions. The cutoff for a positive result was 0.35 IU/mL. The  
22  
23 reaction of a nil control and a mitogen control were within the range provided by the  
24  
25 manufacturer. After collection of blood samples for QFT-GIT, trained nurses  
26  
27 administered the TST using 2 TU of PPD RT23 (Statens Serum Institut, Copenhagen,  
28  
29 Denmark) by the Mantoux method, and inspected the presence of BCG scars. Tuberculin  
30  
31 indurations were measured 48-72 h after injection using the palpation method, and a  
32  
33 diameter of 10 mm or more was defined as positive. All TST procedures followed the  
34  
35 national guidelines issued by the CDC of Taiwan [14].  
36  
37  
38  
39  
40  
41  
42

### 43 **Data collection**

44  
45 We examined the DDMP database, and abstracted demographic data and  
46  
47 information on DM care in the same year when each subject was recruited. This  
48  
49 included duration of DM, glycated hemoglobin (HbA1c), blood pressure, lipid profile,  
50  
51 renal function, and other related cardiovascular disease risk factors. We also linked  
52  
53 individual data with the TB registry at the local health authority to assess whether each  
54  
55 study subject had a prior history of TB or contact with TB.  
56  
57  
58  
59  
60

## Statistical analysis

Although both TST and IGRA indicate a cellular immune response to Mycobacterium tuberculosis (MTB) and are useful for the diagnosis of LTBI, the two tests identified different population with distinct immunologic processes [15]. Tuberculin reactivity represents the cumulative effect of previous TB infection (caused by recent and/or remote infection) because after infection with TB, positive results often remain lifelong until old age. On the contrary, IGRA has a dose-response relationship with recent TB exposure but it wanes rapidly [15, 16]. Thus, for adjusting for the bias of DM-related TB infection resulting from the occurrence of TB before DM (Figure 1a) as explained earlier, we used the result of the QFT-GIT as a surrogate of LTBI status in the logistic regression models designed to identify risk factors for LTBI. The TST results were then included in the models for controlling the confounding of remote TB infection. We also tested for effect modification of BCG protection by age and DM by including interactions terms (ie. Age×BCG scar and DM×BCG scar) in the regression analysis. All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

## Patient and Public Involvement

Patients and/or the public were not involved in this study. There are no plans to disseminate the results of the research to study participants.

## RESULTS

### Characteristics of Participants

We ultimately enrolled 2948 patients in the DM group and 453 non-DM subjects in CC group, and included all of these individuals in the final analysis (Figure 2). The



1  
2  
3 mean duration of DM in the DM group was 9.0 years (standard deviation [SD]=6.6) and  
4 nearly half of these patients achieved good glycemic control (*i.e.* HbA1c < 7%) (Table  
5 1). The DM group had a greater mean age, higher percentages of males and smokers,  
6  
7 greater prevalences of obesity, chronic kidney disease (CKD), and prior history of TB.  
8  
9 The DM group also had a greater prevalence of tuberculin reactivity ( $\geq 15$ mm) and of  
10  
11 QFT-GIT positivity, and a higher proportion of indeterminate results (Table 1).  
12  
13  
14  
15  
16  
17  
18  
19

### 20 **TST and QFT-GIT results**

21  
22 The presence of BCG scars had no effect on the tuberculin reactivity of the DM  
23 group (Figure 3a). TST positivity decreased with age, and was higher in the DM group  
24 than the CC group, except among the elderly (60+ years). Figure 3b shows that QFT-  
25  
26 GIT positivity of DM group was highest among those with no BCG scars, and that  
27  
28 positivity declined dramatically in those more than 60 years-old. In contrast, the rate of  
29  
30 QFT-GIT positivity in those with BCG scars gradually increased with age. For each age  
31  
32 group, there was an inverse correlation between number of BCG scars and QFT-GIT  
33  
34 positivity. Individuals in the CC group with BCG scars had the lowest QFT-GIT  
35  
36 positivity, but elderly individuals from the CC group (age 70+) had the highest QFT-  
37  
38 GIT positivity. Generally, the concordance between the TST and QFT-GIT was low  
39  
40  
41  
42  
43  
44  
45 (Supplementary Table 1).  
46  
47  
48  
49

### 50 **Effect of DM and other factors on risk of LTBI**

51  
52 Multivariate regression analysis indicates DM significantly increased the risk of  
53  
54 LTBI after controlling for major confounders (aOR=1.67; 95%CI, 1.18-2.38). This risk  
55  
56 was similar after adjustment for tuberculin reactivity (aOR=1.59; 95% CI, 1.11-2.28). In  
57  
58 addition, the presence of LTBI increased with age. For age older than 70 years, TST  
59  
60

1  
2  
3 adjustment had a marked effect and changed its aOR from 4.27 (95% CI, 2.83-6.44) to  
4  
5 2.98 (95% CI, 2.00-4.44). Other variables, such as current smoking, CKD, and prior  
6  
7 history of TB, were also significant risk factors for LTBI, and their effects were similar  
8  
9 with or without adjustment for tuberculin reactivity. Notably, the presence of a BCG  
10  
11 scar had a significantly protective effect on LTBI (aOR=0.66 [95%CI, 0.51-0.85])  
12  
13 (Table 2, Model 2); those with 1 scar had an aOR of 0.69 (95% CI, 0.52-0.90) and those  
14  
15 with 2 or more scars had an aOR of 0.49 (95% CI, 0.36-0.67) (Table 2, Model 1).  
16  
17  
18  
19  
20  
21

22 The interaction term DM×BCG scar added to the regression model did not show a  
23  
24 significant effect. For assessing effect modification of the association between LTBI and  
25  
26 BCG vaccination by age, the people aged younger than 50 years without BCG scar were  
27  
28 taken as the reference group. The aORs of the interaction terms (age×BCG scar) were  
29  
30 0.2 (95%CI, 0.0-0.7) for ages < 50 years, 0.3 (95%CI, 0.1-1.5) for ages 50-60 years, 0.5  
31  
32 (95%CI, 0.1-2.4) for ages 60-70 years, and 5.2 (95%CI, 1.1-25.4) for ages 70+ years  
33  
34 respectively. (Table 2, Model 1)  
35  
36  
37  
38  
39  
40  
41

42 Comorbidities, such as hyperlipidemia, hypertension, and abnormal body mass  
43  
44 index (BMI), had no significant associations with LTBI. We further investigated the  
45  
46 effect of long duration DM and poor glyceimic control by dividing the DM group into  
47  
48 four sub-groups according to duration of DM and HbA1c level, and then compared the  
49  
50 risk of LTBI of these different sub-groups, using the CC group as a reference. All of the  
51  
52 DM sub-groups had similar risks for LTBI. This indicates that long duration of DM and  
53  
54 poor glyceimic control had no effect on the risk of LTBI (Supplementary Table 2).  
55  
56  
57  
58 However, among the DM group, those people with DM history for 5+ years had an aOR  
59  
60

of 0.78 (95%CI, 0.63-0.96) (Table 2, Model 1).

## DISCUSSION

Very few studies have examined the effect of DM on the risk of LTBI in high TB incidence areas and simultaneously taken into account confounding effects resulting from protection of BCG vaccination and remote TB infection. To our best knowledge, this is the first study to describe the association between LTBI and BCG vaccination in diabetes population. In this community-based study, we found BCG had a protective effect on TB infection in adults with an aOR of 0.66 (95%CI, 0.51-0.85), which did not vary by the status of DM. This effect also persisted in middle-aged adulthood until it waned in old age. Meanwhile, by use of stringent diagnostic criteria and adjusting for major confounding variables, our multivariate analysis indicated that DM had a positive association with risk of LTBI (aOR, 1.59 [95%CI, 1.11-2.28]). A recently published population-based study in US, a country where BCG is not generally recommended for use, using similar diagnostic criteria as this study, showed DM was associated with LTBI with an aOR 1.5 (95% CI, 1.0–2.2) [7], very similar to our finding.

Until recently, there has been a scarcity of evidence on whether BCG can prevent acquisition of TB infection because conventional measurement of LTBI utilizing TST cannot distinguish if a positive response is due to MTB infection, or BCG vaccination, or non-tuberculous mycobacterial (NTM) infection [9, 17]. Unlike TST, the recently developed IGRAs use MTB specific antigens that do not cross react with BCG. Studies have been conducted to investigate BCG protection on LTBI measured as positive responses on IGRA. A recent meta-analysis of 14 studies and 3855 child or adolescent participants (< 16 years) suggested that BCG is associated with protection from TB

1  
2  
3 infection (overall risk ratio, 0.81; 95% CI, 0.71 to 0.92) [9]. Three additional studies in  
4 high burden TB countries, not included in the meta-analysis, revealed that the protection  
5 existed in young adults decades after BCG vaccination with aORs ranging from 0.6  
6 (95%CI, 0.2–1.8) to 0.52 (95% CI, 0.32-0.85) [10, 18, 19], close to our estimate.  
7  
8  
9

10  
11  
12 Additionally, since in our regression model, the aORs of interaction terms  
13 DM×BCG raised dramatically to 5.2 (95%CI, 1.1-25.4) in the age group of 70+ years, it  
14 is reasonable to assume that BCG protection against TB infection may last 60 years and  
15 then waned, an estimate in accordance with previous observations [18]. These findings  
16 raised the concern that researchers must be cautious in interpreting DM-LTBI  
17 association when confounding of BCG was not controlled, especially in settings with  
18 high BCG coverage. For example, the lowered OR of DM after adjustment (crude OR  
19 2.68 vs. aOR 1.59) (Table 2) simply reflected that the CC group had higher proportion of  
20 subjects with BCG scars than the DM group (Table 1).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Since DM is a progressive disease, longer diabetes duration was found to be a major predictor of DM-related complications and death, independent of glyceemic control [19]. An earlier study also revealed the risk of developing TB disease increased among those with increasing diabetes severity [2]. Thus, in this study, we investigated the combined effect of longer duration of DM and poor glyceemic control (Supplementary Table 2). We found they did not affect the risk of LTBI. While association between glyceemic control and risk of TB was not observed either in other researches targeting patients with long-established DM [20, 21], there have been several studies on cases of pre-diabetes or untreated early diabetes supported the hypothesis [1, 5, 7]. Diabetes patients with poor glyceemic control and longer disease duration tend to have a smaller social network and less contact with their family members or friends [22, 23]. This may

1  
2  
3 reduce the opportunity of social contact with TB cases and trumped the risk for recent  
4  
5 TB infection.  
6  
7  
8  
9

10 Many of the subjects with DM in the present study also smoked (14.7%), had  
11 abnormal BMIs (overweight and obese, 58.4%; underweight, 1.7%), CKD (32.2%),  
12 prior history of TB (2.1%), and advanced age (58.6% older than 60 years), and these  
13 may also be risk factors for TB [24-26]. We found that each factor alone had only a mild  
14 to moderate association with LTBI (Table 2) after adjustment of BCG protection.  
15 However, when an individual has all of these other factors as well as DM, there may be  
16 a particularly high-risk of LTBI, especially in those who are elderly. For example, male  
17 DM patients older than 60 years who smoke have an aOR of LTBI up to 6.7 (derived by  
18 summation of the estimated regression coefficients). Conventional targeted screening for  
19 LTBI mostly focuses on host variables and the environment, such as infectiousness of  
20 index cases and contact patterns, but seldom consider the effects of multiple factors  
21 simultaneously [27, 28]. Our results underscore the necessity of incorporating DM,  
22 BCG, TST results and related risk factors to develop a composite scoring system that  
23 improves the efficacy of LTBI screening programs.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 There are some limitations in our study. First, although the *in vivo* TST and *ex vivo*  
46 IGRAs are the only two methods available for diagnosing LTBI, there is concern that  
47 immune dysfunction in DM may compromise the performance of these tests [5].  
48 Reduced sensitivity of the QFT-GIT and TST in elderly diabetics (Figure 3a, 3b) may  
49 lead to false negatives, and therefore underestimate the effect of DM. Second, all DM  
50 patients were enrolled from the DDMP, an intervention designed to facilitate lifestyle  
51 modification in patients with DM [12]. Thus, these study subjects may have better  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 general health status, and hence lower risk of TB infection, than DM patients from the  
4  
5 general population [21].  
6  
7  
8  
9

10 The comorbidity of TB and DM is due to the interaction between DM-impaired  
11 immunity and the occurrence of active TB by endogenous reactivation (Figure 1a) or  
12 exogenous new or reinfection (Figure 1b, 1c) [1, 5]. This process is further complicated  
13  
14 by the protection conferred from BCG vaccination, remote TB infection, social  
15 environment, the co-existence of multiple non-communicable risk factors and other  
16 related comorbidities and complications [5, 26, 29]. We tried to control for all possible  
17 confounders, but this remains challenging due to the lack of a gold standard for  
18 diagnosis of LTBI and the presence of only limited tools to identify DM patients who  
19 have the greatest risk of progressing to active TB. More studies are therefore required to  
20 identify the predictive value for progression to active TB based on IGRA and/or TST  
21 results in patients with DM. There is an ongoing longitudinal study of the present study  
22 cohort.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

## 40 CONCLUSION

41  
42 In conclusion, our study demonstrated BCG had an apparent protective effect on  
43 TB infection in adults and there were a 1.59-fold increased risk of LTBI in patients with  
44 DM from a geographic area that has a high incidence of TB and a high coverage of BCG  
45 vaccination. This finding suggests that practitioners should incorporate BCG  
46 vaccination, comorbidities and other coexisting risk factors, in addition to DM, to better  
47 identify high-risk groups and enhance the efficacy of targeted screening for LTBI.  
48  
49 Efficacy of new vaccines against TB infection should be a major focus of TB vaccine  
50 development.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DECLARATIONS

### Authors' contributions:

- 1 Guarantor of integrity of the entire study: Ching-Hsiung Lin, Shu-Chen Kuo, Yen-Po Yeh, Shih-Te Tu
- 2 Study concepts: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 3 Study design: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 4 Definition of intellectual content: Ching-Hsiung Lin, Shu-Chen Kuo, Ih-Jen Su, Yee-Chun Chen, Yen-Po Yeh, Shih-Te Tu
- 5 Literature research: Shu-Chen Kuo, Ming-Chia Hsieh, Chia-Yu Chi, Yee-Chun Chen, Horng Yunn Dou
- 6 Clinical studies: Ming-Chia Hsieh, Ching-Hsiung Lin, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin, Yen-Po Yeh, Shih-Te Tu
- 7 Experimental studies: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Horng Yunn Dou Jen-Shiou Lin, Yen-Po Yeh, Shih-Te Tu
- 8 Data acquisition: Ming-Chia Hsieh, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin
- 9 Data analysis: Shu-Chen Kuo, Ming-Chia Hsieh, Shang-Yun Ho, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Fan-Chen Tseng, Yen-Po Yeh, Shih-Te Tu
- 10 Statistical analysis: Ming-Chia Hsieh, Fan-Chen Tseng, Yen-Po Yeh,
- 11 Manuscript preparation: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu

1  
2  
3 12 Manuscript editing: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po  
4  
5 Yeh, Shih-Te Tu  
6

7  
8 13 Manuscript review: Ching-Hsiung Lin, Ming-Chia Hsieh, Sheng-Hao Lin , Yee-  
9  
10 Chun Chen, Yen-Po Yeh, Shih-Te Tu  
11

## 12 13 14 15 **Acknowledgement**

16  
17 The authors wish to acknowledge the assistance of Statistics experts: Dr. Chao-Chih Lai  
18  
19 from Emergency Department, Taipei City Hospital, Ren-Ai Branch, Taiwan and  
20  
21 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health,  
22  
23 National Taiwan University, Division Biostatistics, Taipei Taiwan; Professor Hsiu-Hsi  
24  
25 Chen from Graduate Institute of Epidemiology and Preventive Medicine, College of  
26  
27 Public Health, National Taiwan University, Division Biostatistics, Taipei Taiwan; Dr.  
28  
29 ChenYang Hsu from Graduate Institute of Epidemiology and Prevention Medicine,  
30  
31 College of Public Health, National Taiwan University. The authors also express special  
32  
33 thanks to the Physician at the Changhua Health Bureau and the Physician at Department  
34  
35 of Metabolism, ChangHua Christian Hospital for their assistance in the community-  
36  
37 based study. This work was supported by the "Innovation and Policy Center for  
38  
39 Population Health and Sustainable Environment (Population Health Research Center,  
40  
41 PHRC), College of Public Health, National Taiwan University" from The Featured  
42  
43 Areas Research Center Programme within the framework of the Higher Education  
44  
45 Sprout Project by the Ministry of Education (MOE) in Taiwan.  
46  
47  
48  
49  
50  
51  
52  
53

## 54 **Conflict of interest statements:**

55  
56 All authors declare that they have no conflict of interest.  
57  
58  
59  
60



**Role of funding source:**

This study is supported by the Funding sponsorship plan of National Health Research Institutes: “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan -A study on Evolution, Toxicity and Drug Resistance of Mycobacterium Tuberculosis (IV-102-SP-08)” and “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan - A Study on the Evolution of Tuberculosis Genes and Transcripts in Tuberculosis Recurrence(IV-103-SP-06, IV-104-SP-06)”; the Funding sponsorship plan of ChangHua Christian Hospital: “Risk assessment of TB reactivation and efficacy of preventive therapy in latent TB infection population in Changhua county (102-CCH-PRJ-03)”. Yen-Po Yeh is supported by the Ministry of Science and Technology grant (grant number MOST 107-3017-F-002-003) and The Featured Areas Research Center Programme within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). The founders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Ethics committee approval:**

All participants provided signed informed consent before enrollment. Both studies were approved by the Institutional Review Board of the Changhua Christian Hospital (numbers IRB:CCH-130102 and IRB:CCH-111012).

**Availability of data and material:** Not applicable.

**Consent for publication:** Not applicable.

**REFERENCE**

- 1 Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;9:737-46.
- 2 Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011;9:81.
- 3 World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. WHO/HTM/TB.2013.04. World Health Organization, Geneva; 2013.
- 4 World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes 2011. [http://www.who.int/diabetes/publications/tb\\_diabetes2011/en/](http://www.who.int/diabetes/publications/tb_diabetes2011/en/). Accessed April 12, 2017.
- 5 Restrepo BI. Diabetes and Tuberculosis. *Microbiol Spectr*. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0023-2016.
- 6 Lee MR, Huang YP, Kuo YT, Luo CH, Shih YJ, Shu CC, et al. Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. *Clin Infect Dis*. 2017; 64:719-27.
- 7 Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. *Clin Infect Dis* 2017;65:2060-8.
- 8 Yeh YP, Luh DL, Chang SH, et al. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. *Trans R Soc Trop Med Hyg* 2005;99:509-16.
- 9 Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis.

1  
2  
3 BMJ 2014;349:g4643.  
4

5  
6 10 Chan PC, Yang CH, Chang LY, et al. Lower prevalence of tuberculosis infection in  
7 BCG vaccinees: a cross-sectional study in adult prison inmates. *Thorax* 2013;68:263-8.  
8

9  
10 11 CDC, DoH, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. Centres  
12 for Disease Control, Department of Health, R.O.C. (Taiwan) 2014.  
13

14  
15 12 Yeh YP, Chang CJ, Hsieh ML, et al. Overcoming disparities in diabetes care: eight  
16 years' experience changing the diabetes care system in Changhua, Taiwan. *Diabetes Res*  
17 *Clin Pract* 2014;106 Suppl 2:S314-22.  
18

19  
20 21 22 Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model:  
23 design, implementation, and analysis of 42,387 participants. *Cancer* 2004;100:1734-43.  
24

25  
26 27 28 CDC, DoH, R.O.C. (Taiwan). TB Control Manual, 2nd edn Centres for Disease  
29 Control, Department of Health, R.O.C. (Taiwan), 2009.

30  
31 32 33 34 35 36 37 38 39 15 Lai CC, Hsu CY, Hsieh YC, Yeh YP, Chen HH. The effect of combining  
40 QuantiFERON-TB Gold In-Tube test with tuberculin skin test on the detection of active  
41 tuberculosis. *Trans R Soc Trop Med Hyg.* 2018 May 1;112(5):245-251. doi:  
42 10.1093/trstmh/try043.  
43

44  
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 16 Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test  
and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis  
infection in an intermediate tuberculosis-burden country. *JAMA* 2005;293:2756-61.

17 Hawn TR, Day TA, Scriba TJ, et al. Tuberculosis vaccines and prevention of  
infection. *Microbiol Mol Biol Rev* 2014;78:650-71.

18 Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG  
vaccine in American Indians and Alaska Natives: A 60-year follow-up study. *JAMA*  
2004;291:2086-91.

19 Herrington WG, Alegre-Diaz J, Wade R, et al. Effect of diabetes duration and

glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study. *Lancet Diabetes Endocrinol* 2018;6:455-63.

20 Leegaard A, Riis A, Kornum JB, *et al.* Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. *Diabetes Care* 2011;34:2530-5.

21 Pealing L, Wing K, Mathur R, *et al.* Risk of tuberculosis in patients with diabetes: population based cohort study using the UK Clinical Practice Research Datalink. *BMC Med* 2015;13:135.

22 Yokobayashi K, Kawachi I, Kondo K, *et al.* Association between Social Relationship and Glycemic Control among Older Japanese: JAGES Cross-Sectional Study. *PLoS One* 2017;12:e0169904.

23 Sparring V, Nystrom L, Wahlstrom R, *et al.* Diabetes duration and health-related quality of life in individuals with onset of diabetes in the age group 15-34 years - a Swedish population-based study using EQ-5D. *BMC Public Health* 2013;13:377.

24 Romanowski K, Clark EG, Levin A, *et al.* Tuberculosis and chronic kidney disease: an emerging global syndemic. *Kidney Int* 2016;90:34-40.

25 Horsburgh CR, Jr., O'Donnell M, Chamblee S, *et al.* Revisiting rates of reactivation tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 2010;182:420-5.

26 Dye C, Bourdin Trunz B, Lonnroth K, *et al.* Nutrition, diabetes and tuberculosis in the epidemiological transition. *PLoS One* 2011;6:e21161.

27 Fox GJ, Barry SE, Britton WJ, *et al.* Contact investigation for tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2013;41:140-56.

28 Aissa K, Madhi F, Ronsin N, *et al.* Evaluation of a model for efficient screening of tuberculosis contact subjects. *Am J Respir Crit Care Med* 2008;177:1041-7.

29 Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. *Eur J Immunol* 2014;44:617-26.

## TABLES

**Table 1.** Characteristics of the DM group and the community comparison (CC) group.

	DM group (n=2948)	CC group (n=453)	p
Age, years			
Mean (SD)	61.5 (9.3)	51.3 (10.5)	<b>&lt;0.001</b>
<50	304 (10.3%)	209 (46.1%)	
50-59	918 (31.1%)	137 (30.2%)	<b>&lt;0.001</b>
60-69	1123 (38.1%)	91 (20.1%)	
≥70	603 (20.5%)	16 (3.5%)	
Sex			
Male	1468 (49.8%)	109 (24.1%)	<b>&lt;0.001</b>
Female	1480 (50.2%)	344 (75.9%)	
Prior history of TB			
Yes	61 (2.1%)	4 (0.9%)	0.0852
No	2887 (97.9%)	449 (99.1%)	
History of contact with TB			
Yes	115 (3.9%)	65 (14.3%)	<b>&lt;0.001</b>
No	2283 (77.4%)	388 (85.7%)	
Unknown	550 (18.7%)	0 (0.0%)	
BCG scar			
Yes	2436 (82.6%)	440 (97.1%)	
1 scar	1481 (50.2%)		
2 scar	934 (31.7%)		<b>&lt;0.001</b>
≥2 scars	21 (0.7%)		
No	502 (17.0%)	13 (2.9%)	
Unknown	10 (0.3%)		
BMI, kg/m <sup>2</sup>			
Underweight (<18.5)	50 (1.7%)	7 (1.5%)	<b>&lt;0.001</b>
Normal (18.5-24.9)	1175 (39.9%)	274 (60.5%)	
Overweight (25-29.9)	1265 (42.9%)	149 (32.9%)	
Obese (≥30)	458 (15.5%)	23 (5.1%)	
Smoking status			
Current	433 (14.7%)	31 (6.8%)	<b>&lt;0.001</b>
Quit	434 (14.7%)	34 (7.5%)	
Never	2081 (70.6%)	388 (85.7%)	
Triglycerides, mg/dL			
<150 mg/dl	1962 (66.6%)	371 (81.9%)	<b>&lt;0.001</b>
≥150	986 (33.4%)	82 (18.1%)	
HDL-C*			
Low	1336 (45.3%)	299 (66.0%)	<b>&lt;0.001</b>
Ideal	1612 (54.7%)	154 (34.0%)	

1				
2				
3				
4	CKD**			
5	Yes	948 (32.2%)	57 (12.6%)	<b>&lt;0.001</b>
6	No	1941 (65.8%)	375 (82.8%)	
7	Unknown	59 (2.0%)	21 (4.6%)	
8				
9	Duration of diabetes, years			
10	mean (SD)	9.0 (6.6)		
11	≤5	1077 (36.5%)		
12	>5	1871 (63.5%)		
13				
14				
15	HbA1c			
16	Mean (SD)	7.4 (1.5)		
17	<7%	1400 (47.5%)		
18	≥7%	1548 (52.5%)		
19	Unknown	6 (0.2%)		
20				
21	TST positive			
22	≥5 mm	2280 (77.3%)	350 (77.3%)	0.9895
23	<5 mm	668 (22.7%)	103 (22.7%)	
24	≥10 mm	1665 (56.5%)	251 (55.4%)	0.6974
25	<10 mm	1283 (43.5%)	202 (44.6%)	
26	≥15 mm	890 (30.2%)	112 (24.7%)	<b>0.0211</b>
27	<15mm	2058 (69.8%)	341 (75.3%)	
28				
29				
30	QFT-GIT			
31	Positive	623 (21.1%)	44 (9.7%)	<b>&lt;0.001</b>
32	Negative	2144 (72.7%)	406 (89.6%)	
33	Indeterminate	181 (6.1%)	3 (0.7%)	

Abbreviations: SD, standard deviation; HbA1c, glycated hemoglobin; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube.

\*Low HDL-C: <40 mg/dL (males) and <50 mg/dL (females).

\*\*CKD (chronic kidney disease) was assessed by the Modification of Diet in Renal Disease (MDRD) study equation, using the estimated glomerular filtration rate (eGFR).

**Table 2.** Logistic regression analysis of factors associated with LTBI in the DM group (model 1) and in the DM and CC groups combined (model 2), without and with adjustment for TST results.

Variable	Model 1. DM group (n = 2767)				Model 2. DM and CC groups (n = 3217)		
	Crude OR (95% CI)	aOR (95% CI)	aOR (95% CI) (TST adjustment)		Crude OR (95% CI)	aOR (95% CI)	aOR (95% CI) (TST adjustment)
			Age×BCG <sup>s</sup>				
DM					2.68 (1.94-3.71)	1.67 (1.18-2.38)	1.59 (1.11-2.28)
BCG scar							
No	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>		<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Yes					0.51 (0.41-0.63)	0.73 (0.57-0.93)	0.66 (0.51-0.85)
1 scar	0.63 (0.50-0.79)	0.76 (0.59-0.99)	0.69 (0.52-0.90)				
2+ scars	0.43 (0.33-0.56)	0.55 (0.41-0.74)	0.49 (0.36-0.67)				
TST 10+	3.85 (3.11-4.76)		4.77 (3.80-5.99)	4.75 (3.79-5.97)	3.66 (2.99-4.49)		4.56 (3.67-5.66)
Age, years							
<50	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
50-59	1.63 (1.11-2.41)	1.85 (1.23-2.79)	2.20 (1.45-3.32)	1.33 (0.27-6.48)	1.98 (1.42-2.76)	1.86 (1.30-2.65)	2.12 (1.48-3.05)
60-69	2.12 (1.45-3.09)	2.28 (1.52-3.41)	2.96 (1.97-4.47)	0.73 (0.16-3.39)	2.52 (1.83-3.49)	2.25 (1.58-3.20)	2.77 (1.93-3.97)
≥70	3.19 (2.15-4.71)	2.84 (1.82-4.45)	4.35 (2.74-6.89)	1.10 (0.24-4.95)	4.07 (2.89-5.71)	2.98 (2.00-4.44)	4.27 (2.83-6.44)
Male	1.28 (1.07-1.54)	1.19 (0.94-1.50)	1.09 (0.85-1.38)	1.11 (0.87-1.41)	1.41 (1.19-1.68)	1.22 (0.98-1.52)	1.12 (0.89-1.41)
Smoking							
Never	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Current	1.53 (1.20-1.93)	1.61 (1.2-2.15)	1.36 (1.00-1.83)	1.38 (1.02-1.86)	1.54 (1.22-1.95)	1.49 (1.13-1.97)	1.28 (0.95-1.71)
Quit	0.93 (0.71-1.21)	0.88 (0.64-1.2)	0.82 (0.59-1.13)	0.83 (0.60-1.15)	1.00 (0.77-1.29)	0.87 (0.64-1.17)	0.82 (0.60-1.11)
CKD	1.46 (1.21-1.76)	1.20 (0.98-1.47)	1.30 (1.05-1.60)	1.29 (1.04-1.59)	1.56 (1.31-1.87)	1.17 (0.96-1.42)	1.26 (1.03-1.55)
PHx TB	2.99 (1.78-5.03)	2.35 (1.36-4.05)	2.21 (1.25-3.91)	2.16 (1.22-3.83)	2.95 (1.78-4.89)	2.17 (1.28-3.68)	2.08 (1.19-3.63)
TB contact	0.82 (0.50-1.32)	0.83 (0.50-1.36)	0.75 (0.45-1.25)	0.73 (0.43-1.22)	0.75 (0.50-1.13)	0.92 (0.60-1.40)	0.86 (0.55-1.33)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

---

DM 5+ yrs	0.95 (0.79-1.15)	0.84 (0.69-1.02)	0.79 (0.64-0.97)	0.78 (0.63-0.96)
A1C 7+%	0.91 (0.76-1.08)	0.91 (0.75-1.10)	0.91 (0.75-1.11)	0.92 (0.76-1.12)
Age×BCG§				
<50				0.16 (0.04-0.75)
50-59				0.34 (0.08-1.52)
60-69				0.54 (0.12-2.40)
≥70				5.23 (1.08-25.40)

---

Abbreviations: DM, the diabetes mellitus; CC, community comparison; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST 10+, results of tuberculin skin test  $\geq$  10mm; BMI, body mass index; CKD, chronic kidney disease; DM 5+ yrs, duration of diabetes mellitus  $\geq$  5 years; A1C, glycated hemoglobin. PHx TB, prior history of TB. § Measure of effect modification of the association between LTBI and BCG scar by age on multiplicative scale.

For peer review only



## FIGURE LEGENDS

**Figure 1** Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

**Figure 2** Patient selection and enrolment in the DM group (left) and the CC group (right).

Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

**Figure 3** Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DM group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

Figure 1




Figure 1 Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

294x192mm (120 x 120 DPI)

Figure 2





Figure 2 Patient selection and enrolment in the DM group (left) and the CC group (right). Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

99x65mm (300 x 300 DPI)

Figure 3

(a)



(b)




Figure 3 Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DM group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

99x127mm (300 x 300 DPI)

**Supplementary Table 1. Agreement between TST and QFT-GIT**

Results	Overall n = 3217			DM group n = 2767			CC group n = 450		
	TST cut point			TST cut point			TST cut point		
	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm
TST+/QFT-GIT+	613	528	363	37	32	23	576	496	340
TST-/QFT-GIT-	664	1252	1950	95	188	318	569	1064	1632
TST+/QFT-GIT-	1886	1298	600	311	218	88	1575	1080	512
TST-/QFT-GIT+	54	139	304	7	12	21	47	127	283
Agreement%	39.7%	55.3%	71.9%	29.3%	48.9%	75.8%	41.4%	56.4%	71.3%
Kappa (95% CI)	0.09 (0.74-0.10)	0.17 (0.15-0.20)	0.27 (0.23-0.30)	0.10 (0.08-0.12)	0.19 (0.16-0.22)	0.27 (0.23-0.31)	0.02 (-0.01-0.05)	0.06 (0.01-0.11)	0.18 (0.09-0.28)

Abbreviations: TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube; CI, confidence interval.

Test results with an indeterminate QFT-GIT response are not included in the table.

**Supplementary Table 2. Combined effects of glycaemic control (HbA1c) and duration of DM on risk of latent tuberculosis infection without and with adjustment for TST results.**

Variables	Crude OR (95% CI)	aOR* (95% CI)	aOR* (95% CI) (TST adjustment)
Community comparison group	Reference	Reference	Reference
A1C $\geq$ 7%, duration >5 years	2.49 (1.77-3.52)	1.42 (0.97-2.07)	1.33 (0.90-1.96)
A1C $\geq$ 7%, duration $\leq$ 5 years	2.71 (1.84-3.98)	1.87 (1.24-2.82)	1.80 (1.18-2.74)
A1C <7%, duration >5 years	2.84 (1.99-4.04)	1.67 (1.13-2.46)	1.54 (1.03-2.28)
A1C <7%, duration $\leq$ 5 years	2.81 (1.95-4.04)	1.84 (1.24-2.72)	1.82 (1.22-2.72)

Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST, tuberculin skin test; A1C, glycated hemoglobin.

\*The multivariable model adjusted for the comorbidities indicated in Table 3, Model 2.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9
Objectives	3	State specific objectives, including any pre-specified hypotheses	9
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10-12
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-12
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	10-11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	14
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	14-16
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	17-21
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	17-21
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	17-21
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	17-21
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17-21
		(b) Report category boundaries when continuous variables were categorized	17-21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	21-25
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	24
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	24-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	24-25
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.  
**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Effect of Diabetes Mellitus on Risk of Latent TB Infection in A High TB Incidence Area: A Community-based Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029948.R2
Article Type:	Original research
Date Submitted by the Author:	06-Aug-2019
Complete List of Authors:	<p>Lin, Ching-Hsiung; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; Chung Shan Medical University, School of Medicine</p> <p>Kuo, Shu-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsieh, Ming-Chia; China Medical University, Graduate Institute of Integrative Medicine; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Ho, Shang-Yun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Su, Ih-Jen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Sheng-Hao; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; MingDao University, Department of Holistic Wellness</p> <p>Chi, Chia-Yu; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology; National Cheng Kung University Hospital, Department of Pediatrics</p> <p>Su, Shih-Li; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Liao, Chiung-Ying; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Chen, Yee-Chun; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsu, Shang-Ren; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Huang, Yuan-Chun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Tseng, Fan-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Wang, Shu Yi; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Dou, Horng Yunn; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Shi-Dou; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Lin, Jen-Shiou; Changhua Christian hospital, Department of Laboratory Medicine</p> <p>Tu, Shih-Te; Changhua Christian Hospital, Department of Internal</p>

	Medicine Yeh, Yen-Po; National Taiwan University, Innovation and Policy Center for Population Health and Sustainable Environment; Changhua Public Health Bureau
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Immunology (including allergy), Respiratory medicine
Keywords:	Diabetes Mellitus, Tuberculosis < INFECTIOUS DISEASES, Latent Infection, Bacillus Calmette–Guérin vaccination, Interferon gamma release assay, Tuberculin skin test

SCHOLARONE™  
Manuscripts

## Effect of Diabetes Mellitus on Risk of Latent TB Infection in A High TB Incidence

### Area: A Community-based Study in Taiwan

**Running title:** Individuals with diabetes have a moderately increased risk of latent TB infection.

Ching-Hsiung Lin, MD, PHD<sup>1,2,3,4#</sup> Shu-Chen Kuo, MD<sup>5#</sup> Ming-Chia Hsieh, MD, PHD<sup>6,7</sup> Shang-Yun Ho, MD<sup>8</sup> Ih-Jen Su, MD, PHD<sup>5</sup> Sheng-Hao Lin, MD, PHD<sup>1,3</sup> Chia-Yu Chi, MD<sup>5,9</sup> Shih-Li Su, MD, PHD<sup>7</sup> Chiung-Ying Liao, MD<sup>8</sup> Yee-Chun Chen, MD, PHD<sup>5</sup> Shang-Ren Hsu, MD<sup>7</sup> Yuan-Chun Huang, MD<sup>8</sup> Fan-Chen Tseng, PHD<sup>5</sup> Shu Yi Wang, MD<sup>7</sup> Horng Yunn Dou, PHD<sup>5</sup> Shi-Dou Lin, MD<sup>7</sup> Jen-Shiou Lin, MD, PHD<sup>10</sup> (Ching-Hsiung Lin from Changhua Research Alliance for Tuberculosis Elimination) on behalf of Changhua Research Alliance for Tuberculosis Elimination,<sup>11</sup> Shih-Te Tu, MD<sup>7\*</sup> Yen-Po Yeh, MD, PHD<sup>12,13\*</sup>

<sup>1</sup> Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua

<sup>2</sup> School of Medicine, Chung Shan Medical University, Taichung, Taiwan

<sup>3</sup> Department of Holistic Wellness, MingDao University, Changhua, Taiwan

<sup>4</sup> Institute of Genomics and Bioinformatics

<sup>5</sup> National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan

<sup>6</sup> Graduate Institute of Integrative Medicine, China Medical University, Taichung, Taiwan

<sup>7</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine,

1  
2  
3 Changhua Christian Hospital, Changhua, Taiwan  
4

5 <sup>8</sup> Department of Medical Imaging, ChangHua Christian Hospital  
6

7 <sup>9</sup> Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan  
8  
9

10 <sup>10</sup> Department of Laboratory Medicine, Changhua Christian hospital  
11

12 <sup>11</sup> ChangHua Christian Hospital, Lukang Christian Hospita, Erlin Christian Hospital,  
13  
14 Yunlin Christian Hospital (Physician of Pulmonary Medicine and Department of  
15  
16 Metabolism); Physician of Changhua county township health clinics, Infectious Diseases  
17  
18 and Vaccine Institute, National Health Research Institutes.  
19

20  
21 <sup>12</sup> Changhua County Public Health Bureau  
22

23  
24 <sup>13</sup> Innovation and Policy Center for Population Health and Sustainable Environment,  
25  
26 College of Public Health, National Taiwan University, Taipei, Taiwan  
27  
28

29  
30  
31 # Ching-Hsiung Lin and Shu-Chen Kuo are co-first author.  
32  
33

34  
35  
36  
37 \*Corresponding authors:  
38

39 Yen-Po Yeh  
40

41  
42 Changhua County Public Health Bureau  
43

44  
45 Tel: 886-4-7115141  
46

47 Fax: 886-4-7115141  
48

49 Email: lgyeh@hotmail.com  
50  
51

52  
53 **Word Count: 3200**  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objective:** To investigate the association between diabetes and latent tuberculosis infections (LTBIs) in high TB incidence areas

**Design:** Community-based comparison study

**Setting:** Outpatient diabetes clinics at 4 hospitals and 13 health centers in urban and rural townships. A community-based screening program was used to recruit non-diabetic participants.

**Participants:** A total of 2948 patients with diabetes aged older than 40 years were recruited, and 453 non-diabetic participants from the community were enrolled.

**Primary and secondary outcome measures:** The interferon-gamma release assay (IGRA) and the tuberculin skin test were used to detect LTBI. The IGRA result was used as a surrogate of LTBI in logistic regression analysis.

**Results:** Diabetes was significantly associated with LTBI ([aOR] = 1.59; 95% CI, 1.11-2.28) and age correlated positively with LTBI. Many subjects with diabetes also had additional risk factors (current smokers [aOR]=1.28; 95% CI, 0.95-1.71], comorbid chronic kidney disease [aOR = 1.26; 95% CI, 1.03-1.55], and prior history of TB [aOR = 2.08; 95% CI, 1.19-3.63]). The presence of BCG scar was protective (aOR = 0.66 ; 95% CI, 0.51-0.85). Duration of diabetes and poor glycemic control were unrelated to the risk of LTBI.

**Conclusion:** There was a moderately increased risk of LTBI in diabetes patients from this high TB incidence area. This finding suggests LTBI screening for the diabetics be combined with other risk factors and comorbidities of TB to better identify high-risk groups and improve the efficacy of targeted screening for LTBI.

**Keywords:** Diabetes Mellitus, Tuberculosis, Latent Infection, Bacillus Calmette–Guérin

1  
2  
3 vaccination, Interferon-gamma release assay, Tuberculin skin test  
4  
5  
6  
7

### 8 **Strengths and limitations of this study**

9

- 10 1. The strengths of this study are the adoption of stringent diagnostic criteria for DM and  
11 comprehensiveness of information obtained from community-based programs.  
12  
13 2. Protection of BCG vaccination, remote TB infection and other important potential  
14 confounding variables were controlled for assessing the DM-LTBI association.  
15  
16 3. The study limitations are the reduced sensitivity of the QFT-GIT and TST in elderly  
17 diabetics and better general health status among the DM group.  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Abbreviations**

27

28 Bacillus Calmette–Guérin (BCG)  
29

30 Changhua Christian Healthcare System (CCHS)  
31

32 Changhua Community-based Integrated Screening (CHCIS)  
33

34 Chronic kidney disease (CKD)  
35

36 Diabetes mellitus (DM)  
37

38 Glycated hemoglobin (HbA1c)  
39

40 Interferon-gamma release assay (IGRA)  
41

42 Latent TB infection (LTBI)  
43

44 Tuberculin skin test (TST)  
45

46 Tuberculosis (TB)  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## BACKGROUND

The co-occurrence of diabetes mellitus (DM) and tuberculosis (TB) cannot be overemphasized because of the high prevalence of each disease throughout the world [1]. Previous studies found that DM affects TB disease presentation, leads to poor treatment outcomes, and increases the risk for active TB [1, 2]. The recently published World Health Organization guideline recommends screening for active TB with DM [3], but it remains elusive whether screening and treatment of latent TB infections (LTBIs) should be prioritized to target individuals with DM [1, 4-6].

There is only limited information on the LTBI status of patients with DM. Most of antecedent relevant studies were in low TB incidence countries [7] or based on selected population by identifying DM in high-risk populations, such as TB contacts, immunocompromised patients with comorbid DM, or crisis-affected people [6]. The results of these studies are also inconsistent, mainly due to the different methods used to ascertain DM status (*e.g.* self-report, medical records, or laboratory testing) and differences in the control of potentially important confounders [1, 5-7].

In high TB incidence areas, where most of TB infection occurred at young age before the onset of DM [8], the temporal relationship between DM and TB infection is different from that in low incidence areas (Figure 1a-1b v.s. 1c) [6]. This temporal characteristic may lead to non-differential misclassification of DM-related TB infection in cross-sectional studies and therefore bias the association toward the null (Figure 1a) [6]. It is also worth noting that Bacillus Calmette–Guérin (BCG) vaccine is widely used in high burden TB countries for childhood immunization against TB. Recent studies found BCG vaccine has a protective effect against TB infection in children [9] and can even last into adulthood [10]. Although several researches have been devoted to assessment of DM-LTBI association, rather less attention has been paid to confounding

1  
2  
3 from the protection conferred by BCG vaccination in settings where coverage of BCG  
4  
5 vaccination in study subjects was high.  
6  
7

8 In this study, using data from community-based programs in an area with a high  
9  
10 incidence of TB and a high coverage of BCG vaccination, we assessed the overall risk of  
11  
12 LTBI in people with and without DM by carefully controlling for potential confounders,  
13  
14 specifically including BCG vaccination, risk of remote TB infection, comorbidities,  
15  
16 important lifestyle factors and DM severity.  
17  
18  
19  
20

## 21 **METHODS**

22  
23 We conducted a community-based study that comprised DM and non-DM subjects  
24  
25 by combining two community-based programs to investigate the effect of DM on risk of  
26  
27 LTBI in Changhua, a county in Taiwan with a TB incidence of 58.7 per 100000 and a  
28  
29 BCG vaccination coverage of around 99% in 2012 [11]. The first program recruited the  
30  
31 DM group from patients registered in the Changhua Diabetes Shared Care program  
32  
33 (CHDSC) [12] to participate in the LTBI survey. The second recruited the community  
34  
35 comparison (CC) group from participants of a community-based LTBI screening  
36  
37 program [13]. Due to the lack of a gold-standard test for LTBI, the tuberculin skin test  
38  
39 (TST) was used in parallel with the interferon-gamma release assay (IGRA). All  
40  
41 participants provided signed informed consent before enrollment. Both studies were  
42  
43 approved by the Institutional Review Board of the Changhua Christian Hospital  
44  
45 (numbers IRB:CCH-130102 and IRB:CCH-111012).  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **DM group**

55  
56 Nearly 60% of DM patients in Changhua were enrolled in the national diabetes  
57  
58 disease management program (DDMP) and registered in the CHDSC [12]. These  
59  
60



1  
2  
3 enrollees were suitable to be included as the study subjects, because their DM status had  
4  
5 been ascertained by certified physicians who provided diabetes care according to  
6  
7 national guidelines. We prospectively invited all those registered DM cases aged older  
8  
9 than 40 years when they presented to outpatient diabetes clinics of the Changhua  
10  
11 Christian Healthcare System (CCHS) or 13 nearby health centers in the surrounding  
12  
13 townships from April 1, 2013 to December 31, 2013. CCHS comprises one medical  
14  
15 center and three branch hospitals, distributed evenly at different locations of the county,  
16  
17 and covers urban and rural areas. Thus, the participants of this study were a  
18  
19 representative sample of the total DM population.  
20  
21  
22  
23

24 All study subjects were screened for pulmonary TB based on respiratory symptoms  
25  
26 and chest X-rays upon entry into the study. Suspected cases submitted sputum  
27  
28 specimens for acid-fast bacilli smears and culture. The diagnosis of TB was confirmed  
29  
30 by chest specialists. Subjects were excluded if they had active pulmonary TB, a life  
31  
32 expectancy of less than 2 years, metastatic cancer, or organ failure (*e.g.* severe liver  
33  
34 disease [Child-Pugh Class B or C]) except chronic renal failure. The included eligible  
35  
36 DM cases then received a TST and IGRA for detection of LTBI.  
37  
38  
39  
40  
41  
42

### 43 **Community comparison group**

44 The Changhua Community-based Integrated Screening (CHCIS) program, which  
45  
46 began in 2005, screens for neoplastic and non-neoplastic diseases (including DM and  
47  
48 pulmonary TB) [13]. The method used to screen for pulmonary TB was the same as that  
49  
50 used in the DM group. We invited all consecutive attendees of the CHCIS program  
51  
52 within the major catchment area of the CCHS to participate in LTBI screening in May 1,  
53  
54 2011. Participants with known DM or newly screened DM (*i.e.* fasting plasma glucose  
55  
56 [FPG]  $\geq$  126 mg/dL) were excluded.  
57  
58  
59  
60

## Tests for LTBI

Venous blood was collected for the QuantiFERON-TB Gold In-Tube test (QFT-GIT; Cellestis, Carnegie, Australia), which was performed in 2 stages, according to the manufacturer's instructions. The cutoff for a positive result was 0.35 IU/mL. The reaction of a nil control and a mitogen control were within the range provided by the manufacturer. After collection of blood samples for QFT-GIT, trained nurses administered the TST using 2 TU of PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) by the Mantoux method, and inspected the presence of BCG scars. Tuberculin indurations were measured 48-72 h after injection using the palpation method, and a diameter of 10 mm or more was defined as positive. All TST procedures followed the national guidelines issued by the CDC of Taiwan [14].

## Data collection

We examined the DDMP database, and abstracted demographic data and information on DM care in the same year when each subject was recruited. This included duration of DM, glycated hemoglobin (HbA1c), blood pressure, lipid profile, renal function, and other related cardiovascular disease risk factors. We also linked individual data with the TB registry at the local health authority to assess whether each study subject had a prior history of TB or contact with TB.

## Statistical analysis

Although both TST and IGRA indicate a cellular immune response to *Mycobacterium tuberculosis* (MTB) and are useful for the diagnosis of LTBI, the two tests identified different population with distinct immunologic processes [15].

1  
2  
3 Substantial discordance of TST and IGRA has been found in previous studies [15, 16].  
4  
5 Nevertheless, IGRA has a dose–response relationship with recent TB exposure and it  
6  
7 wanes rapidly [15, 16]. It may be better than TST at detecting recent rather than remote  
8  
9 TB infection. Thus, we used the result of the QFT-GIT as a surrogate of LTBI status to  
10  
11 estimate univariate odds ratios (ORs) and 95% confidence intervals (CIs) using a logistic  
12  
13 regression model. Variables that met p-values less than 0.2 at univariable analysis were  
14  
15 retained for the multivariable model, which also incorporated standard  
16  
17 sociodemographic variables such as age and gender. The multivariable model was fitted  
18  
19 to generate adjusted odds ratios (aOR) of the association between LTBI and DM by  
20  
21 comparing the DM group with the CC group and adjusting for other independent  
22  
23 variables including age, gender, BCG scar, smoking, prior history of TB, contact with  
24  
25 TB and comorbid chronic kidney disease etc.  
26  
27  
28  
29

30  
31 Since tuberculin reactivity was known to represent the cumulative effect of  
32  
33 previous TB infection, we further included the TST results in the models in attempt to  
34  
35 control the confounding of remote TB infection (i.e. TB infection acquired at young age  
36  
37 before the onset of DM [Figure 1a]). All analyses were conducted using SAS version 9.3  
38  
39 (SAS Institute Inc., Cary, NC, USA).  
40  
41  
42  
43  
44

#### 45 **Patient and Public Involvement**

46  
47 Patients and/or the public were not involved in this study. There are no plans to  
48  
49 disseminate the results of the research to study participants.  
50  
51  
52

## 53 **RESULTS**

### 54 **Characteristics of Participants**

55  
56 We ultimately enrolled 2948 patients in the DM group and 453 non-DM subjects in  
57  
58  
59  
60

1  
2  
3 CC group, and included all of these individuals in the final analysis (Figure 2). The  
4  
5 mean duration of DM in the DM group was 9.0 years (standard deviation [SD]=6.6) and  
6  
7 nearly half of these patients achieved good glycemic control (*i.e.* HbA1c < 7%) (Table  
8  
9 1). The DM group had a greater mean age, higher percentages of males and smokers,  
10  
11 greater prevalences of obesity, chronic kidney disease (CKD), and prior history of TB.  
12  
13 The DM group also had a greater prevalence of tuberculin reactivity ( $\geq 15$ mm) and of  
14  
15 QFT-GIT positivity, and a higher proportion of indeterminate results (Table 1).  
16  
17  
18  
19  
20  
21

### 22 **TST and QFT-GIT results**

23  
24 The presence of BCG scars had no effect on the tuberculin reactivity of the DM  
25  
26 group (Figure 3a). TST positivity decreased with age, and was higher in the DM group  
27  
28 than the CC group, except among the elderly (60+ years). Figure 3b shows that QFT-  
29  
30 GIT positivity of DM group was highest among those with no BCG scars, and that  
31  
32 positivity declined dramatically in those more than 60 years-old. In contrast, the rate of  
33  
34 QFT-GIT positivity in those with BCG scars gradually increased with age. For each age  
35  
36 group, there was an inverse correlation between number of BCG scars and QFT-GIT  
37  
38 positivity. Individuals in the CC group with BCG scars had the lowest QFT-GIT  
39  
40 positivity, but elderly individuals from the CC group (age 70+) had the highest QFT-  
41  
42 GIT positivity. Generally, the concordance between the TST and QFT-GIT was low  
43  
44 (Supplementary Table 1).  
45  
46  
47  
48  
49  
50  
51

### 52 **Effect of DM and other factors on risk of LTBI**

53  
54 Multivariate regression analysis indicates DM significantly increased the risk of  
55  
56 LTBI after controlling for major confounders (aOR=1.67; 95%CI, 1.18-2.38). This risk  
57  
58 was similar after adjustment for tuberculin reactivity (aOR=1.59; 95% CI, 1.11-2.28). In  
59  
60

1  
2  
3 addition, the presence of LTBI increased with age. For age older than 70 years, TST  
4 adjustment had a marked effect and changed its aOR from 4.27 (95% CI, 2.83-6.44) to  
5 2.98 (95% CI, 2.00-4.44). Other variables, such as current smoking, CKD, and prior  
6 history of TB, were also significant risk factors for LTBI, and their effects were similar  
7 with or without adjustment for tuberculin reactivity. Notably, the presence of a BCG  
8 scar had a significantly protective effect on LTBI (aOR=0.66 [95%CI, 0.51-0.85])  
9 (Table 2).

10  
11  
12 Comorbidities, such as hyperlipidemia, hypertension, and abnormal body mass  
13 index (BMI), had no significant associations with LTBI. We further investigated the  
14 effect of long duration DM and poor glycaemic control by dividing the DM group into  
15 four sub-groups according to duration of DM and HbA1c level, and then compared the  
16 risk of LTBI of these different sub-groups, using the CC group as a reference. All of the  
17 DM sub-groups had similar risks for LTBI. This indicates that long duration of DM and  
18 poor glycaemic control had no effect on the risk of LTBI (Supplementary Table 2).

## 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 **DISCUSSION**

39  
40 Very few studies have examined the effect of DM on the risk of LTBI in high TB  
41 incidence areas and simultaneously taken into account confounding effects resulting  
42 from protection of BCG vaccination and remote TB infection. To our best knowledge,  
43 this is the first study of this kind. The key strengths of this study included adoption of  
44 stringent diagnostic criteria for DM and comprehensiveness of information obtained  
45 from community-based programs, which enabled thorough adjustment for important  
46 potential confounding variables. Our multivariate analysis indicated that DM had a  
47 positive association with risk of LTBI (aOR, 1.59 [95%CI, 1.11-2.28]). This finding has  
48 profound implications.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 A recent systematic review concluded the pooled odds ratio estimate for DM on  
7 risk of LTBI was 1.18 (95% CI, 1.06–1.30) [6]. Reasons for the different results from  
8 our study could be related to differences in the populations studied, methods for pooling  
9 results from distinct measurements for LTBI (i.e. TST versus IGRA), ascertainment of  
10 diabetes status by self-reports or medical records, and lack of control for several major  
11 confounders. By contrast, a recently published population-based study in US, a country  
12 where BCG is not generally recommended for use, using similar diagnostic criteria as  
13 this study, showed DM was associated with LTBI with an aOR 1.5 (95% CI, 1.0–2.2)  
14 [7], very similar to our finding.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Although there is abundant evidence on the positive association of DM and active  
29 TB, it is uncertain whether DM increases the susceptibility to TB infection or accelerates  
30 the progression from infection to clinical disease (Figure 1) [1, 5]. More recent studies  
31 found DM increased the risk of active TB disease with aORs ranging from 1.3-2.6, or no  
32 significant effect at all [17-19]. The strength of the association of DM and LTBI in our  
33 study was comparable to these estimates, and was particularly close to the results of  
34 Peeling et al.; like our study, Peeling et al. also examined DM patients under chronic  
35 disease management [19]. The observations above provide indirect evidence that  
36 increased susceptibility to TB infection might play a major contributory role in the  
37 occurrence of active TB in the diabetics. However, we must be cautious in this  
38 interpretation, because most new infections among LTBI subjects are attributable to  
39 reinfection in high TB incidence areas (Figure 1b). In such cases, LTBI is associated  
40 with a significantly lower risk of progressive TB relative to primary infection (incidence  
41 rate ratio, 0.21) [20]. Consequently, the effect of DM on TB still depends on the extent  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to which the negative impact of DM on the immune response overrides the presumably  
4 immuno-protective effect provided by preexisting LTBI.  
5  
6  
7  
8  
9

10 Since DM is a progressive disease, longer diabetes duration was found to be a  
11 major predictor of DM-related complications and death, independent of glycemic control  
12 [21]. An earlier study also revealed the risk of developing TB disease increased among  
13 those with increasing diabetes severity [2]. Thus, in this study, we investigated the  
14 combined effect of longer duration of DM and poor glycemic control (Supplementary  
15 Table 2). We found they did not affect the risk of LTBI. While association between  
16 glycemic control and risk of TB was not observed either in other researches targeting  
17 patients with long-established DM [17, 19], there have been several studies on cases of  
18 pre-diabetes or untreated early diabetes supported the hypothesis [1, 5, 7]. Diabetes  
19 patients with poor glycemic control and longer disease duration tend to have a smaller  
20 social network and less contact with their family members or friends [22, 23]. This may  
21 reduce the opportunity of social contact with TB cases and trumped the risk for recent  
22 TB infection.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Many of the subjects with DM in the present study also smoked (14.7%), had  
43 abnormal BMIs (overweight and obese, 58.4%; underweight, 1.7%), CKD (32.2%),  
44 prior history of TB (2.1%), and advanced age (58.6% older than 60 years), and these  
45 may also be risk factors for TB [24-26]. We found that each factor alone had only a mild  
46 to moderate association with LTBI (Table 2) after adjustment of BCG protection.  
47 However, when an individual has all of these other factors as well as DM, there may be  
48 a particularly high-risk of LTBI, especially in those who are elderly. For example, male  
49 DM patients older than 60 years who smoke have an aOR of LTBI up to 6.7 (derived by  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 summation of the estimated regression coefficients). Conventional targeted screening for  
4  
5 LTBI mostly focuses on host variables and the environment, such as infectiousness of  
6  
7 index cases and contact patterns, but seldom consider the effects of multiple factors  
8  
9 simultaneously [27, 28]. Our results underscore the necessity of incorporating DM,  
10  
11 BCG, TST results, related risk factors and comorbidities to develop a composite scoring  
12  
13 system that improves the efficacy of LTBI screening programs.  
14  
15  
16  
17  
18

19  
20 There are some limitations in our study. First, although the *in vivo* TST and *ex vivo*  
21  
22 IGRAs are the only two methods available for diagnosing LTBI, there is concern that  
23  
24 immune dysfunction in DM may compromise the performance of these tests [5].  
25  
26 Reduced sensitivity of the QFT-GIT and TST in elderly diabetics (Figure 3a, 3b) may  
27  
28 lead to false negatives, and therefore underestimate the effect of DM. Second, all DM  
29  
30 patients were enrolled from the DDMP, an intervention designed to facilitate lifestyle  
31  
32 modification in patients with DM [12]. Thus, these study subjects may have better  
33  
34 general health status, and hence lower risk of TB infection, than DM patients from the  
35  
36 general population [19]. Third, the differences in the characteristics of the DM group  
37  
38 and the community comparison group suggested selection bias existed between the two  
39  
40 groups. Some unmeasured confounders, such as the exposure of TB related to social  
41  
42 environment and socioeconomic status, may have biased our estimation of effect of DM  
43  
44 on risk of LTBI.  
45  
46  
47  
48  
49  
50

51  
52 The comorbidity of TB and DM is due to the interaction between DM-impaired  
53  
54 immunity and the occurrence of active TB by endogenous reactivation (Figure 1a) or  
55  
56 exogenous new or reinfection (Figure 1b, 1c) [1, 5]. This process is further complicated  
57  
58 by the protection conferred from BCG vaccination, remote TB infection, social  
59  
60



1  
2  
3 environment, the co-existence of multiple non-communicable risk factors and other  
4  
5 related comorbidities and complications [5, 26, 29]. We tried to control for all possible  
6  
7 confounders, but this remains challenging due to the lack of a gold standard for  
8  
9 diagnosis of LTBI and the presence of only limited tools to identify DM patients who  
10  
11 have the greatest risk of progressing to active TB. More studies are therefore required to  
12  
13 identify the predictive value for progression to active TB based on IGRA and/or TST  
14  
15 results in patients with DM. There is an ongoing longitudinal study of the present study  
16  
17 cohort.  
18  
19  
20  
21  
22

## 23 24 **CONCLUSION**

25  
26 In conclusion, our study demonstrated a 1.59-fold increased risk of LTBI in  
27  
28 patients with DM from a geographic area that has a high incidence of TB. This finding  
29  
30 suggests that practitioners should incorporate BCG vaccination, comorbidities and other  
31  
32 coexisting risk factors, in addition to DM, to better identify high-risk groups and  
33  
34 enhance the efficacy of targeted screening for LTBI.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DECLARATIONS

### Authors' contributions:

- 1 Guarantor of integrity of the entire study: Ching-Hsiung Lin, Shu-Chen Kuo, Yen-Po Yeh, Shih-Te Tu
- 2 Study concepts: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 3 Study design: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 4 Definition of intellectual content: Ching-Hsiung Lin, Shu-Chen Kuo, Ih-Jen Su, Yee-Chun Chen, Yen-Po Yeh, Shih-Te Tu
- 5 Literature research: Shu-Chen Kuo, Ming-Chia Hsieh, Chia-Yu Chi, Yee-Chun Chen, Horng Yunn Dou
- 6 Clinical studies: Ming-Chia Hsieh, Ching-Hsiung Lin, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin, Yen-Po Yeh, Shih-Te Tu
- 7 Experimental studies: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Horng Yunn Dou Jen-Shiou Lin, Yen-Po Yeh, Shih-Te Tu
- 8 Data acquisition: Ming-Chia Hsieh, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin
- 9 Data analysis: Shu-Chen Kuo, Ming-Chia Hsieh, Shang-Yun Ho, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Fan-Chen Tseng, Yen-Po Yeh, Shih-Te Tu
- 10 Statistical analysis: Ming-Chia Hsieh, Fan-Chen Tseng, Yen-Po Yeh,
- 11 Manuscript preparation: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu

1  
2  
3 12 Manuscript editing: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po  
4  
5 Yeh, Shih-Te Tu  
6

7  
8 13 Manuscript review: Ching-Hsiung Lin, Ming-Chia Hsieh, Sheng-Hao Lin , Yee-  
9  
10 Chun Chen, Yen-Po Yeh, Shih-Te Tu  
11  
12

### 13 14 15 **Acknowledgement**

16  
17 The authors wish to acknowledge the assistance of Statistics experts: Dr. Chao-Chih Lai  
18  
19 from Emergency Department, Taipei City Hospital, Ren-Ai Branch, Taiwan and  
20  
21 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health,  
22  
23 National Taiwan University, Division Biostatistics, Taipei Taiwan; Professor Hsiu-Hsi  
24  
25 Chen from Graduate Institute of Epidemiology and Preventive Medicine, College of  
26  
27 Public Health, National Taiwan University, Division Biostatistics, Taipei Taiwan; Dr.  
28  
29 ChenYang Hsu from Graduate Institute of Epidemiology and Prevention Medicine,  
30  
31 College of Public Health, National Taiwan University. The authors also express special  
32  
33 thanks to the Physician at the Changhua Health Bureau and the Physician at Department  
34  
35 of Metabolism, ChangHua Christian Hospital for their assistance in the community-  
36  
37 based study. This work was supported by the "Innovation and Policy Center for  
38  
39 Population Health and Sustainable Environment (Population Health Research Center,  
40  
41 PHRC), College of Public Health, National Taiwan University" from The Featured  
42  
43 Areas Research Center Programme within the framework of the Higher Education  
44  
45 Sprout Project by the Ministry of Education (MOE) in Taiwan.  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Conflict of interest statements:**

55  
56 All authors declare that they have no conflict of interest.  
57  
58  
59  
60

**Role of funding source:**

This study is supported by the Funding sponsorship plan of National Health Research Institutes: “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan -A study on Evolution, Toxicity and Drug Resistance of Mycobacterium Tuberculosis (IV-102-SP-08)” and “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan - A Study on the Evolution of Tuberculosis Genes and Transcripts in Tuberculosis Recurrence(IV-103-SP-06, IV-104-SP-06)”; the Funding sponsorship plan of ChangHua Christian Hospital: “Risk assessment of TB reactivation and efficacy of preventive therapy in latent TB infection population in Changhua county (102-CCH-PRJ-03)”. Yen-Po Yeh is supported by the Ministry of Science and Technology grant (grant number MOST 107-3017-F-002-003) and The Featured Areas Research Center Programme within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). The founders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Ethics committee approval:**

All participants provided signed informed consent before enrollment. Both studies were approved by the Institutional Review Board of the Changhua Christian Hospital (numbers IRB:CCH-130102 and IRB:CCH-111012).

**Availability of data and material:** All data relevant to the study are included in the article or uploaded as supplementary information

1  
2  
3 **Consent for publication:** Not applicable.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**REFERENCE**

- 1 Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;9:737-46.
- 2 Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011;9:81.
- 3 World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. WHO/HTM/TB.2013.04. World Health Organization, Geneva; 2013.
- 4 World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes 2011. [http://www.who.int/diabetes/publications/tb\\_diabetes2011/en/](http://www.who.int/diabetes/publications/tb_diabetes2011/en/). Accessed April 12, 2017.
- 5 Restrepo BI. Diabetes and Tuberculosis. *Microbiol Spectr*. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0023-2016.
- 6 Lee MR, Huang YP, Kuo YT, Luo CH, Shih YJ, Shu CC, et al. Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. *Clin Infect Dis*. 2017; 64:719-27.
- 7 Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. *Clin Infect Dis* 2017;65:2060-8.
- 8 Yeh YP, Luh DL, Chang SH, et al. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. *Trans R Soc Trop Med Hyg* 2005;99:509-16.
- 9 Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis.

1  
2  
3 BMJ 2014;349:g4643.  
4

5  
6 10 Chan PC, Yang CH, Chang LY, et al. Lower prevalence of tuberculosis infection in  
7  
8 BCG vaccinees: a cross-sectional study in adult prison inmates. *Thorax* 2013;68:263-8.  
9

10  
11 11 CDC, DoH, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. Centres  
12  
13 for Disease Control, Department of Health, R.O.C. (Taiwan) 2014.

14  
15 12 Yeh YP, Chang CJ, Hsieh ML, et al. Overcoming disparities in diabetes care: eight  
16  
17 years' experience changing the diabetes care system in Changhua, Taiwan. *Diabetes Res*  
18  
19 *Clin Pract* 2014;106 Suppl 2:S314-22.  
20

21  
22 13 Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model:  
23  
24 design, implementation, and analysis of 42,387 participants. *Cancer* 2004;100:1734-43.  
25

26  
27 14 CDC, DoH, R.O.C. (Taiwan). TB Control Manual, 2nd edn Centres for Disease  
28  
29 Control, Department of Health, R.O.C. (Taiwan), 2009.

30  
31 15 Lai CC, Hsu CY, Hsieh YC, Yeh YP, Chen HH. The effect of combining  
32  
33 QuantiFERON-TB Gold In-Tube test with tuberculin skin test on the detection of active  
34  
35 tuberculosis. *Trans R Soc Trop Med Hyg.* 2018 May 1;112(5):245-251. doi:  
36  
37 10.1093/trstmh/try043.  
38

39  
40 16 Kang YA, Lee HW, Yoon HI, *et al.* Discrepancy between the tuberculin skin test  
41  
42 and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis  
43  
44 infection in an intermediate tuberculosis-burden country. *JAMA* 2005;293:2756-61.  
45

46  
47 17 Leegaard A, Riis A, Kornum JB, *et al.* Diabetes, glycemic control, and risk of  
48  
49 tuberculosis: a population-based case-control study. *Diabetes Care* 2011;34:2530-5.  
50

51  
52 18. Kuo MC, Lin SH, Lin CH, Mao IC, Chang SJ, Hsieh MC. Type 2 diabetes: an  
53  
54 independent risk factor for tuberculosis: a nationwide population-based study. *PLoS*  
55  
56 *One.* 2013;8(11):e78924. doi:10.1371/journal.pone.0078924. eCollection 2013.  
57

58  
59 19 Pealing L, Wing K, Mathur R, *et al.* Risk of tuberculosis in patients with diabetes:  
60

1  
2  
3 population based cohort study using the UK Clinical Practice Research Datalink. *BMC*  
4  
5 *Med* 2015;13:135.

6  
7 20. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of  
8  
9 progression to active tuberculosis following reinfection with Mycobacterium  
10  
11 tuberculosis. *Clin Infect Dis*. 2012;54(6):784-91. doi:10.1093/cid/cir951. Epub 2012 Jan  
12  
13 19. 1.

14  
15  
16 21 Herrington WG, Alegre-Diaz J, Wade R, *et al*. Effect of diabetes duration and  
17  
18 glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based  
19  
20 prospective cohort study. *Lancet Diabetes Endocrinol* 2018;6:455-63.

21  
22 22 Yokobayashi K, Kawachi I, Kondo K, *et al*. Association between Social  
23  
24 Relationship and Glycemic Control among Older Japanese: JAGES Cross-Sectional  
25  
26 Study. *PLoS One* 2017;12:e0169904.

27  
28 23 Sparring V, Nystrom L, Wahlstrom R, *et al*. Diabetes duration and health-related  
29  
30 quality of life in individuals with onset of diabetes in the age group 15-34 years - a  
31  
32 Swedish population-based study using EQ-5D. *BMC Public Health* 2013;13:377.

33  
34 24 Romanowski K, Clark EG, Levin A, *et al*. Tuberculosis and chronic kidney disease:  
35  
36 an emerging global syndemic. *Kidney Int* 2016;90:34-40.

37  
38 25 Horsburgh CR, Jr., O'Donnell M, Chamblee S, *et al*. Revisiting rates of reactivation  
39  
40 tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 2010;182:420-5.

41  
42 26 Dye C, Bourdin Trunz B, Lonnroth K, *et al*. Nutrition, diabetes and tuberculosis in  
43  
44 the epidemiological transition. *PLoS One* 2011;6:e21161.

45  
46 27 Fox GJ, Barry SE, Britton WJ, *et al*. Contact investigation for tuberculosis: a  
47  
48 systematic review and meta-analysis. *Eur Respir J* 2013;41:140-56.

49  
50 28 Aissa K, Madhi F, Ronsin N, *et al*. Evaluation of a model for efficient screening of  
51  
52 tuberculosis contact subjects. *Am J Respir Crit Care Med* 2008;177:1041-7.



1  
2  
3 29 Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. *Eur J Immunol*  
4  
5 2014;44:617-26.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## TABLES

**Table 1.** Characteristics of the DM group and the community comparison (CC) group.

	DM group (n=2948)	CC group (n=453)	p
Age, years			
Mean (SD)	61.5 (9.3)	51.3 (10.5)	<b>&lt;0.001</b>
<50	304 (10.3%)	209 (46.1%)	
50-59	918 (31.1%)	137 (30.2%)	<b>&lt;0.001</b>
60-69	1123 (38.1%)	91 (20.1%)	
≥70	603 (20.5%)	16 (3.5%)	
Sex			
Male	1468 (49.8%)	109 (24.1%)	<b>&lt;0.001</b>
Female	1480 (50.2%)	344 (75.9%)	
Prior history of TB			
Yes	61 (2.1%)	4 (0.9%)	0.0852
No	2887 (97.9%)	449 (99.1%)	
History of contact with TB			
Yes	115 (3.9%)	65 (14.3%)	<b>&lt;0.001</b>
No	2283 (77.4%)	388 (85.7%)	
Unknown	550 (18.7%)	0 (0.0%)	
BCG scar		440 (97.1%)	
Yes	2436 (82.6%)		
1 scar	1481 (50.2%)		
2 scar	934 (31.7%)		<b>&lt;0.001</b>
≥ 2 scars	21 (0.7%)	13 (2.9%)	
No	502 (17.0%)		
Unknown	10 (0.3%)		
BMI, kg/m <sup>2</sup>			
Underweight (<18.5)	50 (1.7%)	7 (1.5%)	<b>&lt;0.001</b>
Normal (18.5-24.9)	1175 (39.9%)	274 (60.5%)	
Overweight (25-29.9)	1265 (42.9%)	149 (32.9%)	
Obese (≥30)	458 (15.5%)	23 (5.1%)	
Smoking status			
Current	433 (14.7%)	31 (6.8%)	<b>&lt;0.001</b>
Quit	434 (14.7%)	34 (7.5%)	
Never	2081 (70.6%)	388 (85.7%)	
Triglycerides, mg/dL			
<150 mg/dl	1962 (66.6%)	371 (81.9%)	<b>&lt;0.001</b>
≥150	986 (33.4%)	82 (18.1%)	
HDL-C*			<b>&lt;0.001</b>
Low	1336 (45.3%)	299 (66.0%)	
Ideal	1612 (54.7%)	154 (34.0%)	

1				
2				
3				
4	CKD**			
5	Yes	948 (32.2%)	57 (12.6%)	<b>&lt;0.001</b>
6	No	1941 (65.8%)	375 (82.8%)	
7	Unknown	59 (2.0%)	21 (4.6%)	
8				
9	Duration of diabetes, years			
10	mean (SD)	9.0 (6.6)		
11	≤5	1077 (36.5%)		
12	>5	1871 (63.5%)		
13				
14	HbA1c			
15	Mean (SD)	7.4 (1.5)		
16	<7%	1400 (47.5%)		
17	≥7%	1548 (52.5%)		
18	Unknown	6 (0.2%)		
19				
20	TST positive			
21	≥5 mm	2280 (77.3%)	350 (77.3%)	0.9895
22	<5 mm	668 (22.7%)	103 (22.7%)	
23	≥10 mm	1665 (56.5%)	251 (55.4%)	0.6974
24	<10 mm	1283 (43.5%)	202 (44.6%)	
25	≥15 mm	890 (30.2%)	112 (24.7%)	<b>0.0211</b>
26	<15mm	2058 (69.8%)	341 (75.3%)	
27				
28				
29				
30	QFT-GIT			
31	Positive	623 (21.1%)	44 (9.7%)	<b>&lt;0.001</b>
32	Negative	2144 (72.7%)	406 (89.6%)	
33	Indeterminate	181 (6.1%)	3 (0.7%)	
34				

Abbreviations: SD, standard deviation; HbA1c, glycated hemoglobin; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube.

\*Low HDL-C: <40 mg/dL (males) and <50 mg/dL (females).

\*\*CKD (chronic kidney disease) was assessed by the Modification of Diet in Renal Disease (MDRD) study equation, using the estimated glomerular filtration rate (eGFR).

**Table 2.** Multivariable logistic regression analysis of factors associated with LTBI by comparing the DM group with the community comparison group (n = 3217)

Variable	Crude OR (95% CI)	aOR1 (95% CI)	aOR2 (95% CI)
DM	2.68 (1.94-3.71)	1.67 (1.18-2.38)	1.59 (1.11-2.28)
TST 10+	3.66 (2.99-4.49)		4.56 (3.67-5.66)
BCG scar			
No	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Yes	0.51 (0.41-0.63)	0.73 (0.57-0.93)	0.66 (0.51-0.85)
Age, years			
<50	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
50-59	1.98 (1.42-2.76)	1.86 (1.30-2.65)	2.12 (1.48-3.05)
60-69	2.52 (1.83-3.49)	2.25 (1.58-3.20)	2.77 (1.93-3.97)
≥70	4.07 (2.89-5.71)	2.98 (2.00-4.44)	4.27 (2.83-6.44)
Male	1.41 (1.19-1.68)	1.22 (0.98-1.52)	1.12 (0.89-1.41)
Smoking			
Never	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Current	1.54 (1.22-1.95)	1.49 (1.13-1.97)	1.28 (0.95-1.71)
Quit	1.00 (0.77-1.29)	0.87 (0.64-1.17)	0.82 (0.60-1.11)
Chronic kidney disease	1.56 (1.31-1.87)	1.17 (0.96-1.42)	1.26 (1.03-1.55)
Prior history of TB	2.95 (1.78-4.89)	2.17 (1.28-3.68)	2.08 (1.19-3.63)
TB contact	0.75 (0.50-1.13)	0.92 (0.60-1.40)	0.86 (0.55-1.33)

Abbreviations: DM, the diabetes mellitus; TST 10+, results of tuberculin skin test  $\geq$  10mm; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; aOR1: adjusted odds ratio without adjustment of TST results; aOR2: adjusted odds ratio with adjustment of TST results.

## FIGURE LEGENDS

**Figure 1** Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

**Figure 2** Patient selection and enrolment in the DM group (left) and the CC group (right).

Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

**Figure 3** Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DM group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

Figure 1




Figure 1 Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

89x89mm (600 x 600 DPI)

Figure 2





Figure 2 Patient selection and enrolment in the DM group (left) and the CC group (right). Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

90x90mm (600 x 600 DPI)

Figure 3



Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DMG group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

90x90mm (600 x 600 DPI)



**Supplementary Table 1. Agreement between TST and QFT-GIT**

Results	Overall n = 3217			DM group n = 2767			CC group n = 450		
	TST cut point			TST cut point			TST cut point		
	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm
TST+/QFT-GIT+	613	528	363	37	32	23	576	496	340
TST-/QFT-GIT-	664	1252	1950	95	188	318	569	1064	1632
TST+/QFT-GIT-	1886	1298	600	311	218	88	1575	1080	512
TST-/QFT-GIT+	54	139	304	7	12	21	47	127	283
Agreement%	39.7%	55.3%	71.9%	29.3%	48.9%	75.8%	41.4%	56.4%	71.3%
Kappa (95% CI)	0.09 (0.74-0.10)	0.17 (0.15-0.20)	0.27 (0.23-0.30)	0.10 (0.08-0.12)	0.19 (0.16-0.22)	0.27 (0.23-0.31)	0.02 (-0.01-0.05)	0.06 (0.01-0.11)	0.18 (0.09-0.28)

Abbreviations: TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube; CI, confidence interval.

Test results with an indeterminate QFT-GIT response are not included in the table.

**Supplementary Table 2. Combined effects of glycemic control (HbA1c) and duration of DM on risk of latent tuberculosis infection without and with adjustment of TST results.**

Variables	Crude OR (95% CI)	aOR1 (95% CI)	aOR2 (95% CI)
Community comparison group	Reference	Reference	Reference
A1C $\geq$ 7%, duration >5 years	2.49 (1.77-3.52)	1.42 (0.97-2.07)	1.33 (0.90-1.96)
A1C $\geq$ 7%, duration $\leq$ 5 years	2.71 (1.84-3.98)	1.87 (1.24-2.82)	1.80 (1.18-2.74)
A1C <7%, duration >5 years	2.84 (1.99-4.04)	1.67 (1.13-2.46)	1.54 (1.03-2.28)
A1C <7%, duration $\leq$ 5 years	2.81 (1.95-4.04)	1.84 (1.24-2.72)	1.82 (1.22-2.72)

Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST, tuberculin skin test; A1C, glycated hemoglobin. aOR1: adjusted odds ratio without adjustment of TST results; aOR2: adjusted odds ratio with adjustment of TST results.

\*The multivariable model adjusted for the comorbidities indicated in Table 2.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9
Objectives	3	State specific objectives, including any pre-specified hypotheses	9
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10-12
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-12
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	10-11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	14
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	14-16
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	17-21
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	17-21
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	17-21
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	17-21
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17-21
		(b) Report category boundaries when continuous variables were categorized	17-21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	21-25
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	24
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	24-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	24-25
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.  
**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Effect of Diabetes Mellitus on Risk of Latent TB Infection in A High TB Incidence Area: A Community-based Study in Taiwan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029948.R3
Article Type:	Original research
Date Submitted by the Author:	29-Sep-2019
Complete List of Authors:	<p>Lin, Ching-Hsiung; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; Chung Shan Medical University, School of Medicine</p> <p>Kuo, Shu-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsieh, Ming-Chia; China Medical University, Graduate Institute of Integrative Medicine; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Ho, Shang-Yun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Su, Ih-Jen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Sheng-Hao; Changhua Christian Hospital, Department of Internal Medicine, Division of Chest Medicine; MingDao University, Department of Holistic Wellness</p> <p>Chi, Chia-Yu; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology; National Cheng Kung University Hospital, Department of Pediatrics</p> <p>Su, Shih-Li; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Liao, Chiung-Ying; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Chen, Yee-Chun; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Hsu, Shang-Ren; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Huang, Yuan-Chun; ChangHua Christian Hospital, Department of Medical Imaging</p> <p>Tseng, Fan-Chen; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Wang, Shu Yi; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Dou, Horng Yunn; National Health Research Institutes, National Institute of Infectious Diseases and Vaccinology</p> <p>Lin, Shi-Dou; Changhua Christian Hospital, Department of Internal Medicine</p> <p>Lin, Jen-Shiou; Changhua Christian hospital, Department of Laboratory Medicine</p> <p>Tu, Shih-Te; Changhua Christian Hospital, Department of Internal</p>

	Medicine Yeh, Yen-Po; National Taiwan University, Innovation and Policy Center for Population Health and Sustainable Environment; Changhua Public Health Bureau
<b>Primary Subject Heading</b> :	Infectious diseases
Secondary Subject Heading:	Diabetes and endocrinology, Epidemiology, Public health, Immunology (including allergy), Respiratory medicine
Keywords:	Diabetes Mellitus, Tuberculosis < INFECTIOUS DISEASES, Latent Infection, Bacillus Calmette–Guérin vaccination, Interferon gamma release assay, Tuberculin skin test

SCHOLARONE™  
Manuscripts

## Effect of Diabetes Mellitus on Risk of Latent TB Infection in A High TB Incidence

### Area: A Community-based Study in Taiwan

**Running title:** Individuals with diabetes have a moderately increased risk of latent TB infection.

Ching-Hsiung Lin, MD, PHD<sup>1,2,3,4#</sup> Shu-Chen Kuo, MD<sup>5#</sup> Ming-Chia Hsieh, MD, PHD<sup>6,7</sup> Shang-Yun Ho, MD<sup>8</sup> Ih-Jen Su, MD, PHD<sup>5</sup> Sheng-Hao Lin, MD, PHD<sup>1,3</sup> Chia-Yu Chi, MD<sup>5,9</sup> Shih-Li Su, MD, PHD<sup>7</sup> Chiung-Ying Liao, MD<sup>8</sup> Yee-Chun Chen, MD, PHD<sup>5</sup> Shang-Ren Hsu, MD<sup>7</sup> Yuan-Chun Huang, MD<sup>8</sup> Fan-Chen Tseng, PHD<sup>5</sup> Shu Yi Wang, MD<sup>7</sup> Horng Yunn Dou, PHD<sup>5</sup> Shi-Dou Lin, MD<sup>7</sup> Jen-Shiou Lin, MD, PHD<sup>10</sup> (Ching-Hsiung Lin from Changhua Research Alliance for Tuberculosis Elimination) on behalf of Changhua Research Alliance for Tuberculosis Elimination,<sup>11</sup> Shih-Te Tu, MD<sup>7\*</sup> Yen-Po Yeh, MD, PHD<sup>12,13\*</sup>

<sup>1</sup> Department of Internal Medicine, Division of Chest Medicine, Changhua Christian Hospital, Changhua

<sup>2</sup> School of Medicine, Chung Shan Medical University, Taichung, Taiwan

<sup>3</sup> Department of Holistic Wellness, MingDao University, Changhua, Taiwan

<sup>4</sup> Institute of Genomics and Bioinformatics

<sup>5</sup> National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli, Taiwan

<sup>6</sup> Graduate Institute of Integrative Medicine, China Medical University, Taichung, Taiwan

<sup>7</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine,

1  
2  
3 Changhua Christian Hospital, Changhua, Taiwan  
4

5 <sup>8</sup> Department of Medical Imaging, ChangHua Christian Hospital  
6

7 <sup>9</sup> Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan  
8  
9

10 <sup>10</sup> Department of Laboratory Medicine, Changhua Christian hospital  
11

12 <sup>11</sup> ChangHua Christian Hospital, Lukang Christian Hospita, Erlin Christian Hospital,  
13  
14 Yunlin Christian Hospital (Physician of Pulmonary Medicine and Department of  
15  
16 Metabolism); Physician of Changhua county township health clinics, Infectious Diseases  
17  
18 and Vaccine Institute, National Health Research Institutes.  
19

20  
21 <sup>12</sup> Changhua County Public Health Bureau  
22

23  
24 <sup>13</sup> Innovation and Policy Center for Population Health and Sustainable Environment,  
25  
26 College of Public Health, National Taiwan University, Taipei, Taiwan  
27  
28

29  
30  
31 # Ching-Hsiung Lin and Shu-Chen Kuo are co-first author.  
32  
33

34  
35  
36  
37 \*Corresponding authors:  
38

39 Yen-Po Yeh  
40

41  
42 Changhua County Public Health Bureau  
43

44  
45 Tel: 886-4-7115141  
46

47  
48 Fax: 886-4-7115141  
49

50  
51 Email: lgyeh@hotmail.com  
52  
53

54 **Word Count: 3200**  
55  
56  
57  
58  
59  
60



## ABSTRACT

**Objective:** To investigate the association between diabetes and latent tuberculosis infections (LTBIs) in high TB incidence areas

**Design:** Community-based comparison study

**Setting:** Outpatient diabetes clinics at 4 hospitals and 13 health centers in urban and rural townships. A community-based screening program was used to recruit non-diabetic participants.

**Participants:** A total of 2948 patients with diabetes aged older than 40 years were recruited, and 453 non-diabetic participants from the community were enrolled.

**Primary and secondary outcome measures:** The interferon-gamma release assay (IGRA) and the tuberculin skin test were used to detect LTBI. The IGRA result was used as a surrogate of LTBI in logistic regression analysis.

**Results:** Diabetes was significantly associated with LTBI ([aOR] = 1.59; 95% CI, 1.11-2.28) and age correlated positively with LTBI. Many subjects with diabetes also had additional risk factors (current smokers [aOR=1.28; 95% CI, 0.95-1.71], comorbid chronic kidney disease [aOR = 1.26; 95% CI, 1.03-1.55], and prior history of TB [aOR = 2.08; 95% CI, 1.19-3.63]). The presence of BCG scar was protective (aOR = 0.66 ; 95% CI, 0.51-0.85). Duration of diabetes and poor glycemic control were unrelated to the risk of LTBI.

**Conclusion:** There was a moderately increased risk of LTBI in diabetes patients from this high TB incidence area. This finding suggests LTBI screening for the diabetics be combined with other risk factors and comorbidities of TB to better identify high-risk groups and improve the efficacy of targeted screening for LTBI.

**Keywords:** Diabetes Mellitus, Tuberculosis, Latent Infection, Bacillus Calmette–Guérin

1  
2  
3 vaccination, Interferon-gamma release assay, Tuberculin skin test  
4  
5  
6  
7

### 8 **Strengths and limitations of this study**

9

- 10 1. The strengths of this study are the adoption of stringent diagnostic criteria for DM and  
11 comprehensiveness of information obtained from community-based programs.  
12  
13 2. Protection of BCG vaccination, remote TB infection and other important potential  
14 confounding variables were controlled for assessing the DM-LTBI association.  
15  
16 3. The study limitations are the reduced sensitivity of the QFT-GIT and TST in elderly  
17 diabetics and better general health status among the DM group.  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Abbreviations**

27

28 Bacillus Calmette–Guérin (BCG)  
29

30 Changhua Christian Healthcare System (CCHS)  
31

32 Changhua Community-based Integrated Screening (CHCIS)  
33

34 Chronic kidney disease (CKD)  
35

36 Diabetes mellitus (DM)  
37

38 Glycated hemoglobin (HbA1c)  
39

40 Interferon-gamma release assay (IGRA)  
41

42 Latent TB infection (LTBI)  
43

44 Tuberculin skin test (TST)  
45

46 Tuberculosis (TB)  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## BACKGROUND

The co-occurrence of diabetes mellitus (DM) and tuberculosis (TB) cannot be overemphasized because of the high prevalence of each disease throughout the world [1]. Previous studies found that DM affects TB disease presentation, leads to poor treatment outcomes, and increases the risk for active TB [1, 2]. The recently published World Health Organization guideline recommends screening for active TB with DM [3], but it remains elusive whether screening and treatment of latent TB infections (LTBIs) should be prioritized to target individuals with DM [1, 4-6].

There is only limited information on the LTBI status of patients with DM. Most of antecedent relevant studies were in low TB incidence countries [7] or based on selected population by identifying DM in high-risk populations, such as TB contacts, immunocompromised patients with comorbid DM, or crisis-affected people [6]. The results of these studies are also inconsistent, mainly due to the different methods used to ascertain DM status (*e.g.* self-report, medical records, or laboratory testing) and differences in the control of potentially important confounders [1, 5-7].

In high TB incidence areas, where most of TB infection occurred at young age before the onset of DM [8], the temporal relationship between DM and TB infection is different from that in low incidence areas (Figure 1a-1b v.s. 1c) [6]. This temporal characteristic may lead to non-differential misclassification of DM-related TB infection in cross-sectional studies and therefore bias the association toward the null (Figure 1a) [6]. It is also worth noting that Bacillus Calmette–Guérin (BCG) vaccine is widely used in high burden TB countries for childhood immunization against TB. Recent studies found BCG vaccine has a protective effect against TB infection in children [9] and can even last into adulthood [10]. Although several researches have been devoted to assessment of DM-LTBI association, rather less attention has been paid to confounding

1  
2  
3 from the protection conferred by BCG vaccination in settings where coverage of BCG  
4  
5 vaccination in study subjects was high.  
6  
7

8 In this study, using data from community-based programs in an area with a high  
9  
10 incidence of TB and a high coverage of BCG vaccination, we assessed the overall risk of  
11  
12 LTBI in people with and without DM by carefully controlling for potential confounders,  
13  
14 specifically including BCG vaccination, risk of remote TB infection, comorbidities,  
15  
16 important lifestyle factors and DM severity.  
17  
18  
19  
20

## 21 **METHODS**

22  
23 We conducted a community-based study that comprised DM and non-DM subjects  
24  
25 by combining two community-based programs to investigate the effect of DM on risk of  
26  
27 LTBI in Changhua, a county in Taiwan with a TB incidence of 58.7 per 100000 and a  
28  
29 BCG vaccination coverage of around 99% in 2012 [11]. The first program recruited the  
30  
31 DM group from patients registered in the Changhua Diabetes Shared Care program  
32  
33 (CHDSC) [12] to participate in the LTBI survey. The second recruited the community  
34  
35 comparison (CC) group from participants of a community-based LTBI screening  
36  
37 program [13]. Due to the lack of a gold-standard test for LTBI, the tuberculin skin test  
38  
39 (TST) was used in parallel with the interferon-gamma release assay (IGRA). All  
40  
41 participants provided signed informed consent before enrollment. Both studies were  
42  
43 approved by the Institutional Review Board of the Changhua Christian Hospital  
44  
45 (numbers IRB:CCH-130102 and IRB:CCH-111012).  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **DM group**

55  
56 Nearly 60% of DM patients in Changhua were enrolled in the national diabetes  
57  
58 disease management program (DDMP) and registered in the CHDSC [12]. These  
59  
60

1  
2  
3 enrollees were suitable to be included as the study subjects, because their DM status had  
4  
5 been ascertained by certified physicians who provided diabetes care according to  
6  
7 national guidelines. We prospectively invited all those registered DM cases aged older  
8  
9 than 40 years when they presented to outpatient diabetes clinics of the Changhua  
10  
11 Christian Healthcare System (CCHS) or 13 nearby health centers in the surrounding  
12  
13 townships from April 1, 2013 to December 31, 2013. CCHS comprises one medical  
14  
15 center and three branch hospitals, distributed evenly at different locations of the county,  
16  
17 and covers urban and rural areas. Thus, the participants of this study were a  
18  
19 representative sample of the total DM population.  
20  
21  
22  
23

24 All study subjects were screened for pulmonary TB based on respiratory symptoms  
25  
26 and chest X-rays upon entry into the study. Suspected cases submitted sputum  
27  
28 specimens for acid-fast bacilli smears and culture. The diagnosis of TB was confirmed  
29  
30 by chest specialists. Subjects were excluded if they had active pulmonary TB, a life  
31  
32 expectancy of less than 2 years, metastatic cancer, or organ failure (*e.g.* severe liver  
33  
34 disease [Child-Pugh Class B or C]) except chronic renal failure. The included eligible  
35  
36 DM cases then received a TST and IGRA for detection of LTBI.  
37  
38  
39  
40  
41  
42

### 43 **Community comparison group**

44 The Changhua Community-based Integrated Screening (CHCIS) program, which  
45  
46 began in 2005, screens for neoplastic and non-neoplastic diseases (including DM and  
47  
48 pulmonary TB) [13]. The method used to screen for pulmonary TB was the same as that  
49  
50 used in the DM group. We invited all consecutive attendees of the CHCIS program  
51  
52 within the major catchment area of the CCHS to participate in LTBI screening in May 1,  
53  
54 2011. Participants with known DM or newly screened DM (*i.e.* fasting plasma glucose  
55  
56 [FPG]  $\geq$  126 mg/dL) were excluded.  
57  
58  
59  
60

## Tests for LTBI

Venous blood was collected for the QuantiFERON-TB Gold In-Tube test (QFT-GIT; Cellestis, Carnegie, Australia), which was performed in 2 stages, according to the manufacturer's instructions. The cutoff for a positive result was 0.35 IU/mL. The reaction of a nil control and a mitogen control were within the range provided by the manufacturer. After collection of blood samples for QFT-GIT, trained nurses administered the TST using 2 TU of PPD RT23 (Statens Serum Institut, Copenhagen, Denmark) by the Mantoux method, and inspected the presence of BCG scars. Tuberculin indurations were measured 48-72 h after injection using the palpation method, and a diameter of 10 mm or more was defined as positive. All TST procedures followed the national guidelines issued by the CDC of Taiwan [14].

## Data collection

We examined the DDMP database, and abstracted demographic data and information on DM care in the same year when each subject was recruited. This included duration of DM, glycated hemoglobin (HbA1c), blood pressure, lipid profile, renal function, and other related cardiovascular disease risk factors. We also linked individual data with the TB registry at the local health authority to assess whether each study subject had a prior history of TB or contact with TB.

## Statistical analysis

Although both TST and IGRA indicate a cellular immune response to *Mycobacterium tuberculosis* (MTB) and are useful for the diagnosis of LTBI, the two tests identified different population with distinct immunologic processes [15].

Substantial discordance of TST and IGRA has been found in previous studies [15, 16]. Nevertheless, IGRA has a dose–response relationship with recent TB exposure and it wanes rapidly [15, 16]. It may be better than TST at detecting recent rather than remote TB infection. Thus, we used the result of the QFT-GIT as a surrogate of LTBI status to estimate univariate odds ratios (ORs) and 95% confidence intervals (CIs) using a logistic regression model. Variables that met p-values less than 0.2 at univariable analysis were retained for the multivariable model, which also incorporated standard sociodemographic variables such as age and gender. The multivariable model was fitted to generate adjusted odds ratios (aOR) of the association between LTBI and DM by comparing the DM group with the CC group and adjusting for other independent variables including age, gender, BCG scar, smoking, prior history of TB, contact with TB and comorbid chronic kidney disease etc.

Since tuberculin reactivity was known to represent the cumulative effect of previous TB infection, we further included the TST results in the models in attempt to control the confounding of remote TB infection (i.e. TB infection acquired at young age before the onset of DM [Figure 1a]). All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).

### **Patient and Public Involvement**

Patients and/or the public were not involved in this study. There are no plans to disseminate the results of the research to study participants.

## **RESULTS**

### **Characteristics of Participants**

We ultimately enrolled 2948 patients in the DM group and 453 non-DM subjects in

1  
2  
3 CC group, and included all of these individuals in the final analysis (Figure 2). The  
4  
5 mean duration of DM in the DM group was 9.0 years (standard deviation [SD]=6.6) and  
6  
7 nearly half of these patients achieved good glycemic control (*i.e.* HbA1c < 7%) (Table  
8  
9 1). The DM group had a greater mean age, higher percentages of males and smokers,  
10  
11 greater prevalences of obesity, chronic kidney disease (CKD), and prior history of TB.  
12  
13 The DM group also had a greater prevalence of tuberculin reactivity ( $\geq 15$ mm) and of  
14  
15 QFT-GIT positivity, and a higher proportion of indeterminate results (Table 1).  
16  
17  
18  
19  
20  
21

### 22 **TST and QFT-GIT results**

23  
24 The presence of BCG scars had no effect on the tuberculin reactivity of the DM  
25  
26 group (Figure 3a). TST positivity decreased with age, and was higher in the DM group  
27  
28 than the CC group, except among the elderly (60+ years). Figure 3b shows that QFT-  
29  
30 GIT positivity of DM group was highest among those with no BCG scars, and that  
31  
32 positivity declined dramatically in those more than 60 years-old. In contrast, the rate of  
33  
34 QFT-GIT positivity in those with BCG scars gradually increased with age. For each age  
35  
36 group, there was an inverse correlation between number of BCG scars and QFT-GIT  
37  
38 positivity. Individuals in the CC group with BCG scars had the lowest QFT-GIT  
39  
40 positivity, but elderly individuals from the CC group (age 70+) had the highest QFT-  
41  
42 GIT positivity. Generally, the concordance between the TST and QFT-GIT was low  
43  
44 (Supplementary Table 1).  
45  
46  
47  
48  
49  
50  
51

### 52 **Effect of DM and other factors on risk of LTBI**

53  
54 Multivariate regression analysis indicates DM significantly increased the risk of  
55  
56 LTBI after controlling for major confounders (aOR=1.67; 95%CI, 1.18-2.38). This risk  
57  
58 was similar after adjustment for tuberculin reactivity (aOR=1.59; 95% CI, 1.11-2.28). In  
59  
60



1  
2  
3 addition, the presence of LTBI increased with age. For age older than 70 years, TST  
4 adjustment had a marked effect and changed its aOR from 4.27 (95% CI, 2.83-6.44) to  
5 2.98 (95% CI, 2.00-4.44). Other variables, such as current smoking, CKD, and prior  
6 history of TB, were also significant risk factors for LTBI, and their effects were similar  
7 with or without adjustment for tuberculin reactivity. Notably, the presence of a BCG  
8 scar had a significantly protective effect on LTBI (aOR=0.66 [95%CI, 0.51-0.85])  
9 (Table 2).

10  
11  
12 Comorbidities, such as hyperlipidemia, hypertension, and abnormal body mass  
13 index (BMI), had no significant associations with LTBI. We further investigated the  
14 effect of long duration DM and poor glycaemic control by dividing the DM group into  
15 four sub-groups according to duration of DM and HbA1c level, and then compared the  
16 risk of LTBI of these different sub-groups, using the CC group as a reference. All of the  
17 DM sub-groups had similar risks for LTBI. This indicates that long duration of DM and  
18 poor glycaemic control had no effect on the risk of LTBI (Supplementary Table 2).

## 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 **DISCUSSION**

39  
40 Very few studies have examined the effect of DM on the risk of LTBI in high TB  
41 incidence areas and simultaneously taken into account confounding effects resulting  
42 from protection of BCG vaccination and remote TB infection. To our best knowledge,  
43 this is the first study of this kind. The key strengths of this study included adoption of  
44 stringent diagnostic criteria for DM and comprehensiveness of information obtained  
45 from community-based programs, which enabled thorough adjustment for important  
46 potential confounding variables. Our multivariate analysis indicated that DM had a  
47 positive association with risk of LTBI (aOR, 1.59 [95%CI, 1.11-2.28]). This finding has  
48 profound implications.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 A recent systematic review concluded the pooled odds ratio estimate for DM on  
7 risk of LTBI was 1.18 (95% CI, 1.06–1.30) [6]. Reasons for the different results from  
8 our study could be related to differences in the populations studied, methods for pooling  
9 results from distinct measurements for LTBI (i.e. TST versus IGRA), ascertainment of  
10 diabetes status by self-reports or medical records, and lack of control for several major  
11 confounders. By contrast, a recently published population-based study in US, a country  
12 where BCG is not generally recommended for use, using similar diagnostic criteria as  
13 this study, showed DM was associated with LTBI with an aOR 1.5 (95% CI, 1.0–2.2)  
14 [7], very similar to our finding.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Although there is abundant evidence on the positive association of DM and active  
29 TB, it is uncertain whether DM increases the susceptibility to TB infection or accelerates  
30 the progression from infection to clinical disease (Figure 1) [1, 5]. More recent studies  
31 found DM increased the risk of active TB disease with aORs ranging from 1.3-2.6, or no  
32 significant effect at all [17-19]. The strength of the association of DM and LTBI in our  
33 study was comparable to these estimates, and was particularly close to the results of  
34 Peeling et al.; like our study, Peeling et al. also examined DM patients under chronic  
35 disease management [19]. The observations above provide indirect evidence that  
36 increased susceptibility to TB infection might play a major contributory role in the  
37 occurrence of active TB in the diabetics. However, we must be cautious in this  
38 interpretation, because most new infections among LTBI subjects are attributable to  
39 reinfection in high TB incidence areas (Figure 1b). In such cases, LTBI is associated  
40 with a significantly lower risk of progressive TB relative to primary infection (incidence  
41 rate ratio, 0.21) [20]. Consequently, the effect of DM on TB still depends on the extent  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 to which the negative impact of DM on the immune response overrides the presumably  
4 immuno-protective effect provided by preexisting LTBI.  
5  
6  
7  
8  
9

10 Since DM is a progressive disease, longer diabetes duration was found to be a  
11 major predictor of DM-related complications and death, independent of glycemic control  
12 [21]. An earlier study also revealed the risk of developing TB disease increased among  
13 those with increasing diabetes severity [2]. Thus, in this study, we investigated the  
14 combined effect of longer duration of DM and poor glycemic control (Supplementary  
15 Table 2). We found they did not affect the risk of LTBI. While association between  
16 glycemic control and risk of TB was not observed either in other researches targeting  
17 patients with long-established DM [17, 19], there have been several studies on cases of  
18 pre-diabetes or untreated early diabetes supported the hypothesis [1, 5, 7]. Diabetes  
19 patients with poor glycemic control and longer disease duration tend to have a smaller  
20 social network and less contact with their family members or friends [22, 23]. This may  
21 reduce the opportunity of social contact with TB cases and trumped the risk for recent  
22 TB infection.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Many of the subjects with DM in the present study also smoked (14.7%), had  
43 abnormal BMIs (overweight and obese, 58.4%; underweight, 1.7%), CKD (32.2%),  
44 prior history of TB (2.1%), and advanced age (58.6% older than 60 years), and these  
45 may also be risk factors for TB [24-26]. We found that each factor alone had only a mild  
46 to moderate association with LTBI (Table 2) after adjustment of BCG protection.  
47 However, when an individual has all of these other factors as well as DM, there may be  
48 a particularly high-risk of LTBI, especially in those who are elderly. For example, male  
49 DM patients older than 60 years who smoke have an aOR of LTBI up to 6.7 (derived by  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 summation of the estimated regression coefficients). Conventional targeted screening for  
4  
5 LTBI mostly focuses on host variables and the environment, such as infectiousness of  
6  
7 index cases and contact patterns, but seldom consider the effects of multiple factors  
8  
9 simultaneously [27, 28]. Our results underscore the necessity of incorporating DM,  
10  
11 BCG, TST results, related risk factors and comorbidities to develop a composite scoring  
12  
13 system that improves the efficacy of LTBI screening programs.  
14  
15  
16  
17  
18

19  
20 There are some limitations in our study. First, although the *in vivo* TST and *ex vivo*  
21  
22 IGRAs are the only two methods available for diagnosing LTBI, there is concern that  
23  
24 immune dysfunction in DM may compromise the performance of these tests [5].  
25  
26 Reduced sensitivity of the QFT-GIT and TST in elderly diabetics (Figure 3a, 3b) may  
27  
28 lead to false negatives, and therefore underestimate the effect of DM. Second, all DM  
29  
30 patients were enrolled from the DDMP, an intervention designed to facilitate lifestyle  
31  
32 modification in patients with DM [12]. Thus, these study subjects may have better  
33  
34 general health status, and hence lower risk of TB infection, than DM patients from the  
35  
36 general population [19]. Third, the differences in the characteristics of the DM group  
37  
38 and the community comparison group suggested selection bias existed between the two  
39  
40 groups. Some unmeasured confounders, such as the exposure of TB related to social  
41  
42 environment and socioeconomic status, may have biased our estimation of effect of DM  
43  
44 on risk of LTBI.  
45  
46  
47  
48  
49  
50

51  
52 The comorbidity of TB and DM is due to the interaction between DM-impaired  
53  
54 immunity and the occurrence of active TB by endogenous reactivation (Figure 1a) or  
55  
56 exogenous new or reinfection (Figure 1b, 1c) [1, 5]. This process is further complicated  
57  
58 by the protection conferred from BCG vaccination, remote TB infection, social  
59  
60

1  
2  
3 environment, the co-existence of multiple non-communicable risk factors and other  
4  
5 related comorbidities and complications [5, 26, 29]. We tried to control for all possible  
6  
7 confounders, but this remains challenging due to the lack of a gold standard for  
8  
9 diagnosis of LTBI and the presence of only limited tools to identify DM patients who  
10  
11 have the greatest risk of progressing to active TB. More studies are therefore required to  
12  
13 identify the predictive value for progression to active TB based on IGRA and/or TST  
14  
15 results in patients with DM. There is an ongoing longitudinal study of the present study  
16  
17 cohort.  
18  
19  
20  
21  
22

## 23 24 **CONCLUSION**

25  
26 In conclusion, our study demonstrated a 1.59-fold increased risk of LTBI in  
27  
28 patients with DM from a geographic area that has a high incidence of TB. This finding  
29  
30 suggests that practitioners should incorporate BCG vaccination, comorbidities and other  
31  
32 coexisting risk factors, in addition to DM, to better identify high-risk groups and  
33  
34 enhance the efficacy of targeted screening for LTBI.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DECLARATIONS

### Authors' contributions:

- 1 Guarantor of integrity of the entire study: Ching-Hsiung Lin, Shu-Chen Kuo, Yen-Po Yeh, Shih-Te Tu
- 2 Study concepts: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 3 Study design: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu
- 4 Definition of intellectual content: Ching-Hsiung Lin, Shu-Chen Kuo, Ih-Jen Su, Yee-Chun Chen, Yen-Po Yeh, Shih-Te Tu
- 5 Literature research: Shu-Chen Kuo, Ming-Chia Hsieh, Chia-Yu Chi, Yee-Chun Chen, Horng Yunn Dou
- 6 Clinical studies: Ming-Chia Hsieh, Ching-Hsiung Lin, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin, Yen-Po Yeh, Shih-Te Tu
- 7 Experimental studies: Ching-Hsiung Lin, Shu-Chen Kuo, Ming-Chia Hsieh, Ih-Jen Su, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Horng Yunn Dou Jen-Shiou Lin, Yen-Po Yeh, Shih-Te Tu
- 8 Data acquisition: Ming-Chia Hsieh, Shang-Yun Ho, Sheng-Hao Lin, Shih-Li Su, Chiung-Ying Liao, Shang-Ren Hsu, Yuan-Chun Huang, Shu Yi Wang, Shi-Dou Lin
- 9 Data analysis: Shu-Chen Kuo, Ming-Chia Hsieh, Shang-Yun Ho, Chia-Yu Chi, Chiung-Ying Liao, Yuan-Chun Huang, Fan-Chen Tseng, Yen-Po Yeh, Shih-Te Tu
- 10 Statistical analysis: Ming-Chia Hsieh, Fan-Chen Tseng, Yen-Po Yeh,
- 11 Manuscript preparation: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po Yeh, Shih-Te Tu

1  
2  
3 12 Manuscript editing: Ching-Hsiung Lin, Shu-Chen Kuo, Sheng-Hao Lin, Yen-Po  
4  
5 Yeh, Shih-Te Tu  
6

7  
8 13 Manuscript review: Ching-Hsiung Lin, Ming-Chia Hsieh, Sheng-Hao Lin , Yee-  
9  
10 Chun Chen, Yen-Po Yeh, Shih-Te Tu  
11  
12  
13

### 14 **Acknowledgement**

15  
16  
17 The authors wish to acknowledge the assistance of Statistics experts: Dr. Chao-Chih Lai  
18  
19 from Emergency Department, Taipei City Hospital, Ren-Ai Branch, Taiwan and  
20  
21 Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health,  
22  
23 National Taiwan University, Division Biostatistics, Taipei Taiwan; Professor Hsiu-Hsi  
24  
25 Chen from Graduate Institute of Epidemiology and Preventive Medicine, College of  
26  
27 Public Health, National Taiwan University, Division Biostatistics, Taipei Taiwan; Dr.  
28  
29 ChenYang Hsu from Graduate Institute of Epidemiology and Prevention Medicine,  
30  
31 College of Public Health, National Taiwan University. The authors also express special  
32  
33 thanks to the Physician at the Changhua Health Bureau and the Physician at Department  
34  
35 of Metabolism, ChangHua Christian Hospital for their assistance in the community-  
36  
37 based study. This work was supported by the "Innovation and Policy Center for  
38  
39 Population Health and Sustainable Environment (Population Health Research Center,  
40  
41 PHRC), College of Public Health, National Taiwan University" from The Featured  
42  
43 Areas Research Center Programme within the framework of the Higher Education  
44  
45 Sprout Project by the Ministry of Education (MOE) in Taiwan.  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Conflict of interest statements:**

55  
56 All authors declare that they have no conflict of interest.  
57  
58  
59  
60

**Role of funding source:**

This study is supported by the Funding sponsorship plan of National Health Research Institutes: “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan -A study on Evolution, Toxicity and Drug Resistance of Mycobacterium Tuberculosis (IV-102-SP-08)” and “A New Strategy for Genetics, Pathogenesis, Prevention and Treatment of Pathogens of Important Infectious Diseases in Taiwan - A Study on the Evolution of Tuberculosis Genes and Transcripts in Tuberculosis Recurrence(IV-103-SP-06, IV-104-SP-06)”; the Funding sponsorship plan of ChangHua Christian Hospital: “Risk assessment of TB reactivation and efficacy of preventive therapy in latent TB infection population in Changhua county (102-CCH-PRJ-03)”. Yen-Po Yeh is supported by the Ministry of Science and Technology grant (grant number MOST 107-3017-F-002-003) and The Featured Areas Research Center Programme within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (NTU-107L9003). The founders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Ethics committee approval:**

All participants provided signed informed consent before enrollment. Both studies were approved by the Institutional Review Board of the Changhua Christian Hospital (numbers IRB:CCH-130102 and IRB:CCH-111012).

**Availability of data and material:** All data relevant to the study are included in the article or uploaded as supplementary information



1  
2  
3 **Consent for publication:** Not applicable.  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**REFERENCE**

- 1 Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. *Lancet Infect Dis* 2009;9:737-46.
- 2 Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. *BMC Med* 2011;9:81.
- 3 World Health Organization. Systematic screening for active tuberculosis: principles and recommendations. WHO/HTM/TB.2013.04. World Health Organization, Geneva; 2013.
- 4 World Health Organization. Collaborative framework for care and control of tuberculosis and diabetes 2011. [http://www.who.int/diabetes/publications/tb\\_diabetes2011/en/](http://www.who.int/diabetes/publications/tb_diabetes2011/en/). Accessed April 12, 2017.
- 5 Restrepo BI. Diabetes and Tuberculosis. *Microbiol Spectr*. 2016 Dec;4(6). doi: 10.1128/microbiolspec.TNMI7-0023-2016.
- 6 Lee MR, Huang YP, Kuo YT, Luo CH, Shih YJ, Shu CC, et al. Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. *Clin Infect Dis*. 2017; 64:719-27.
- 7 Martinez L, Zhu L, Castellanos ME, et al. Glycemic Control and the Prevalence of Tuberculosis Infection: A Population-based Observational Study. *Clin Infect Dis* 2017;65:2060-8.
- 8 Yeh YP, Luh DL, Chang SH, et al. Tuberculin reactivity in adults after 50 years of universal bacille Calmette-Guerin vaccination in Taiwan. *Trans R Soc Trop Med Hyg* 2005;99:509-16.
- 9 Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against *Mycobacterium tuberculosis* infection in children: systematic review and meta-analysis.

1  
2  
3 BMJ 2014;349:g4643.  
4

5  
6 10 Chan PC, Yang CH, Chang LY, et al. Lower prevalence of tuberculosis infection in  
7 BCG vaccinees: a cross-sectional study in adult prison inmates. *Thorax* 2013;68:263-8.  
8

9  
10 11 CDC, DoH, R.O.C. (Taiwan). Taiwan Tuberculosis Control Report 2013. Centres  
12 for Disease Control, Department of Health, R.O.C. (Taiwan) 2014.  
13

14  
15 12 Yeh YP, Chang CJ, Hsieh ML, et al. Overcoming disparities in diabetes care: eight  
16 years' experience changing the diabetes care system in Changhua, Taiwan. *Diabetes Res*  
17 *Clin Pract* 2014;106 Suppl 2:S314-22.  
18

19  
20 21 22 Chen TH, Chiu YH, Luh DL, et al. Community-based multiple screening model:  
23 design, implementation, and analysis of 42,387 participants. *Cancer* 2004;100:1734-43.  
24

25  
26 27 28 CDC, DoH, R.O.C. (Taiwan). TB Control Manual, 2nd edn Centres for Disease  
29 Control, Department of Health, R.O.C. (Taiwan), 2009.  
30

31  
32 33 34 35 36 37 38 39 15 Lai CC, Hsu CY, Hsieh YC, Yeh YP, Chen HH. The effect of combining  
40 QuantiFERON-TB Gold In-Tube test with tuberculin skin test on the detection of active  
41 tuberculosis. *Trans R Soc Trop Med Hyg.* 2018 May 1;112(5):245-251. doi:  
42 10.1093/trstmh/try043.  
43

44  
45 46 47 48 49 50 51 52 53 16 Kang YA, Lee HW, Yoon HI, *et al.* Discrepancy between the tuberculin skin test  
44 and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis  
45 infection in an intermediate tuberculosis-burden country. *JAMA* 2005;293:2756-61.  
46

47  
48 49 50 51 52 53 54 55 17 Leegaard A, Riis A, Kornum JB, *et al.* Diabetes, glycemic control, and risk of  
47 tuberculosis: a population-based case-control study. *Diabetes Care* 2011;34:2530-5.  
48

54  
55 56 57 58 59 60 18. Kuo MC, Lin SH, Lin CH, Mao IC, Chang SJ, Hsieh MC. Type 2 diabetes: an  
54 independent risk factor for tuberculosis: a nationwide population-based study. *PLoS*  
55 *One.* 2013;8(11):e78924. doi:10.1371/journal.pone.0078924. eCollection 2013.  
56

57  
58 59 60 19 Pealing L, Wing K, Mathur R, *et al.* Risk of tuberculosis in patients with diabetes:

1  
2  
3 population based cohort study using the UK Clinical Practice Research Datalink. *BMC*  
4  
5 *Med* 2015;13:135.

6  
7  
8 20. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of  
9  
10 progression to active tuberculosis following reinfection with Mycobacterium  
11  
12 tuberculosis. *Clin Infect Dis*. 2012;54(6):784-91. doi:10.1093/cid/cir951. Epub 2012 Jan  
13  
14 19. 1.

15  
16  
17 21 Herrington WG, Alegre-Diaz J, Wade R, *et al*. Effect of diabetes duration and  
18  
19 glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based  
20  
21 prospective cohort study. *Lancet Diabetes Endocrinol* 2018;6:455-63.

22  
23  
24 22 Yokobayashi K, Kawachi I, Kondo K, *et al*. Association between Social  
25  
26 Relationship and Glycemic Control among Older Japanese: JAGES Cross-Sectional  
27  
28 Study. *PLoS One* 2017;12:e0169904.

29  
30  
31 23 Sparring V, Nystrom L, Wahlstrom R, *et al*. Diabetes duration and health-related  
32  
33 quality of life in individuals with onset of diabetes in the age group 15-34 years - a  
34  
35 Swedish population-based study using EQ-5D. *BMC Public Health* 2013;13:377.

36  
37  
38 24 Romanowski K, Clark EG, Levin A, *et al*. Tuberculosis and chronic kidney disease:  
39  
40 an emerging global syndemic. *Kidney Int* 2016;90:34-40.

41  
42  
43 25 Horsburgh CR, Jr., O'Donnell M, Chamblee S, *et al*. Revisiting rates of reactivation  
44  
45 tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 2010;182:420-5.

46  
47  
48 26 Dye C, Bourdin Trunz B, Lonnroth K, *et al*. Nutrition, diabetes and tuberculosis in  
49  
50 the epidemiological transition. *PLoS One* 2011;6:e21161.

51  
52  
53 27 Fox GJ, Barry SE, Britton WJ, *et al*. Contact investigation for tuberculosis: a  
54  
55 systematic review and meta-analysis. *Eur Respir J* 2013;41:140-56.

56  
57  
58 28 Aissa K, Madhi F, Ronsin N, *et al*. Evaluation of a model for efficient screening of  
59  
60 tuberculosis contact subjects. *Am J Respir Crit Care Med* 2008;177:1041-7.

1  
2  
3 29 Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. *Eur J Immunol*  
4  
5 2014;44:617-26.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## TABLES

**Table 1.** Characteristics of the DM group and the community comparison (CC) group.

	DM group (n=2948)	CC group (n=453)	p
Age, years			
Mean (SD)	61.5 (9.3)	51.3 (10.5)	<b>&lt;0.001</b>
<50	304 (10.3%)	209 (46.1%)	
50-59	918 (31.1%)	137 (30.2%)	<b>&lt;0.001</b>
60-69	1123 (38.1%)	91 (20.1%)	
≥70	603 (20.5%)	16 (3.5%)	
Sex			
Male	1468 (49.8%)	109 (24.1%)	<b>&lt;0.001</b>
Female	1480 (50.2%)	344 (75.9%)	
Prior history of TB			
Yes	61 (2.1%)	4 (0.9%)	0.0852
No	2887 (97.9%)	449 (99.1%)	
History of contact with TB			
Yes	115 (3.9%)	65 (14.3%)	<b>&lt;0.001</b>
No	2283 (77.4%)	388 (85.7%)	
Unknown	550 (18.7%)	0 (0.0%)	
BCG scar		440 (97.1%)	
Yes	2436 (82.6%)		
1 scar	1481 (50.2%)		
2 scar	934 (31.7%)		<b>&lt;0.001</b>
≥ 2 scars	21 (0.7%)	13 (2.9%)	
No	502 (17.0%)		
Unknown	10 (0.3%)		
BMI, kg/m <sup>2</sup>			
Underweight (<18.5)	50 (1.7%)	7 (1.5%)	<b>&lt;0.001</b>
Normal (18.5-24.9)	1175 (39.9%)	274 (60.5%)	
Overweight (25-29.9)	1265 (42.9%)	149 (32.9%)	
Obese (≥30)	458 (15.5%)	23 (5.1%)	
Smoking status			
Current	433 (14.7%)	31 (6.8%)	<b>&lt;0.001</b>
Quit	434 (14.7%)	34 (7.5%)	
Never	2081 (70.6%)	388 (85.7%)	
Triglycerides, mg/dL			
<150 mg/dl	1962 (66.6%)	371 (81.9%)	<b>&lt;0.001</b>
≥150	986 (33.4%)	82 (18.1%)	
HDL-C*			<b>&lt;0.001</b>
Low	1336 (45.3%)	299 (66.0%)	
Ideal	1612 (54.7%)	154 (34.0%)	

1				
2				
3				
4	CKD**			
5	Yes	948 (32.2%)	57 (12.6%)	<b>&lt;0.001</b>
6	No	1941 (65.8%)	375 (82.8%)	
7	Unknown	59 (2.0%)	21 (4.6%)	
8				
9	Duration of diabetes, years			
10	mean (SD)	9.0 (6.6)		
11	≤5	1077 (36.5%)		
12	>5	1871 (63.5%)		
13				
14	HbA1c			
15	Mean (SD)	7.4 (1.5)		
16	<7%	1400 (47.5%)		
17	≥7%	1548 (52.5%)		
18	Unknown	6 (0.2%)		
19				
20	TST positive			
21	≥5 mm	2280 (77.3%)	350 (77.3%)	0.9895
22	<5 mm	668 (22.7%)	103 (22.7%)	
23	≥10 mm	1665 (56.5%)	251 (55.4%)	0.6974
24	<10 mm	1283 (43.5%)	202 (44.6%)	
25	≥15 mm	890 (30.2%)	112 (24.7%)	<b>0.0211</b>
26	<15mm	2058 (69.8%)	341 (75.3%)	
27				
28				
29				
30	QFT-GIT			
31	Positive	623 (21.1%)	44 (9.7%)	<b>&lt;0.001</b>
32	Negative	2144 (72.7%)	406 (89.6%)	
33	Indeterminate	181 (6.1%)	3 (0.7%)	

Abbreviations: SD, standard deviation; HbA1c, glycated hemoglobin; BMI, body mass index; HDL-C, high density lipoprotein cholesterol; TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube.

\*Low HDL-C: <40 mg/dL (males) and <50 mg/dL (females).

\*\*CKD (chronic kidney disease) was assessed by the Modification of Diet in Renal Disease (MDRD) study equation, using the estimated glomerular filtration rate (eGFR).

**Table 2.** Multivariable logistic regression analysis of factors associated with LTBI by comparing the DM group with the community comparison group (n = 3217)

Variable	Crude OR (95% CI)	aOR1 (95% CI)	aOR2 (95% CI)
DM	2.68 (1.94-3.71)	1.67 (1.18-2.38)	1.59 (1.11-2.28)
TST 10+	3.66 (2.99-4.49)		4.56 (3.67-5.66)
BCG scar			
No	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Yes	0.51 (0.41-0.63)	0.73 (0.57-0.93)	0.66 (0.51-0.85)
Age, years			
<50	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
50-59	1.98 (1.42-2.76)	1.86 (1.30-2.65)	2.12 (1.48-3.05)
60-69	2.52 (1.83-3.49)	2.25 (1.58-3.20)	2.77 (1.93-3.97)
≥70	4.07 (2.89-5.71)	2.98 (2.00-4.44)	4.27 (2.83-6.44)
Male	1.41 (1.19-1.68)	1.22 (0.98-1.52)	1.12 (0.89-1.41)
Smoking status			
Never	<i>Reference</i>	<i>Reference</i>	<i>Reference</i>
Current	1.54 (1.22-1.95)	1.49 (1.13-1.97)	1.28 (0.95-1.71)
Quit	1.00 (0.77-1.29)	0.87 (0.64-1.17)	0.82 (0.60-1.11)
Chronic kidney disease	1.56 (1.31-1.87)	1.17 (0.96-1.42)	1.26 (1.03-1.55)
Prior history of TB	2.95 (1.78-4.89)	2.17 (1.28-3.68)	2.08 (1.19-3.63)
TB contact	0.75 (0.50-1.13)	0.92 (0.60-1.40)	0.86 (0.55-1.33)

Abbreviations: DM, the diabetes mellitus; TST 10+, results of tuberculin skin test  $\geq$  10mm; OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval. The aOR of DM has been adjusted for age, gender, smoking status, chronic kidney disease, prior history of TB and TB contact in this multivariable logistic regression model. aOR1: adjusted odds ratio without adjustment of TST results; aOR2: adjusted odds ratio with adjustment of TST results.



## FIGURE LEGENDS

**Figure 1** Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

**Figure 2** Patient selection and enrolment in the DM group (left) and the CC group (right).

Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

**Figure 3** Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DM group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

Figure 1




Figure 1 Possible temporal relationships between the onset of DM and the occurrence of TB infection. Circled letters indicate times when DM could possibly affect the pathogenesis of TB (i, increased susceptibility to TB infection; p, accelerated progression from infection to clinical disease). (a) Onset of DM with a pre-existing latent TB infection (LTBI). (b) Onset of DM with a pre-existing LTBI, but before re-infection. (c) Onset of DM before the primary TB infection.

89x89mm (600 x 600 DPI)

Figure 2





Figure 2 Patient selection and enrolment in the DM group (left) and the CC group (right). Abbreviations: TST, tuberculin skin test; IGRA, interferon-gamma release assay; CHCIS, Changhua Community-based Integrated Screening program; DM, diabetes mellitus.

90x90mm (600 x 600 DPI)

Figure 3



Tuberculin skin test (TST) positivity (a) and interferon-gamma release assay (IGRA) positivity (b) in the DMG group (DMG) and the CC group (CCG) according to age and BCG scar status. A tuberculin induration size of 10 mm was used as the cutoff point for both groups.

Abbreviations: TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube.

90x90mm (600 x 600 DPI)

**Supplementary Table 1. Agreement between TST and QFT-GIT**

Results	Overall n = 3217			DM group n = 2767			CC group n = 450		
	TST cut point			TST cut point			TST cut point		
	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm	5 mm	10 mm	15 mm
TST+/QFT-GIT+	613	528	363	37	32	23	576	496	340
TST-/QFT-GIT-	664	1252	1950	95	188	318	569	1064	1632
TST+/QFT-GIT-	1886	1298	600	311	218	88	1575	1080	512
TST-/QFT-GIT+	54	139	304	7	12	21	47	127	283
Agreement%	39.7%	55.3%	71.9%	29.3%	48.9%	75.8%	41.4%	56.4%	71.3%
Kappa (95% CI)	0.09 (0.74-0.10)	0.17 (0.15-0.20)	0.27 (0.23-0.30)	0.10 (0.08-0.12)	0.19 (0.16-0.22)	0.27 (0.23-0.31)	0.02 (-0.01-0.05)	0.06 (0.01-0.11)	0.18 (0.09-0.28)

Abbreviations: TST, tuberculin skin test; QFT-GIT, QuantiFERON-TB Gold In-Tube; CI, confidence interval.

Test results with an indeterminate QFT-GIT response are not included in the table.

**Supplementary Table 2. Combined effects of glycemic control (HbA1c) and duration of DM on risk of latent tuberculosis infection without and with adjustment of TST results.**

Variables	Crude OR (95% CI)	aOR1 (95% CI)	aOR2 (95% CI)
Community comparison group	Reference	Reference	Reference
A1C $\geq$ 7%, duration >5 years	2.49 (1.77-3.52)	1.42 (0.97-2.07)	1.33 (0.90-1.96)
A1C $\geq$ 7%, duration $\leq$ 5 years	2.71 (1.84-3.98)	1.87 (1.24-2.82)	1.80 (1.18-2.74)
A1C <7%, duration >5 years	2.84 (1.99-4.04)	1.67 (1.13-2.46)	1.54 (1.03-2.28)
A1C <7%, duration $\leq$ 5 years	2.81 (1.95-4.04)	1.84 (1.24-2.72)	1.82 (1.22-2.72)

Abbreviations: OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; TST, tuberculin skin test; A1C, glycated hemoglobin. aOR1: adjusted odds ratio without adjustment of TST results; aOR2: adjusted odds ratio with adjustment of TST results.

\*The multivariable model adjusted for the comorbidities indicated in Table 2.

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	4
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	4
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	8-9
Objectives	3	State specific objectives, including any pre-specified hypotheses	9
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	10
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	10
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	10-12
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	11-13
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	11-12
Bias	9	Describe any efforts to address potential sources of bias	-
Study size	10	Explain how the study size was arrived at	10-11
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	10-12
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	13-14
		(b) Describe any methods used to examine subgroups and interactions	13-14
		(c) Explain how missing data were addressed	-
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	-

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	-
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	14
		(b) Give reasons for non-participation at each stage	-
		(c) Consider use of a flow diagram	-
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	14-16
		(b) Indicate number of participants with missing data for each variable of interest	-
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	17-21
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	17-21
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	17-21
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	17-21
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	17-21
		(b) Report category boundaries when continuous variables were categorized	17-21
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	21-25
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	24
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	24-25
Generalisability	21	Discuss the generalisability (external validity) of the study results	24-25
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	28

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.  
**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).